<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD005504.pub2" GROUP_ID="MOVEMENT" ID="135805022109551089" MERGED_FROM="" MODIFIED="2011-03-25 17:26:26 +0100" MODIFIED_BY="Ema Roque" NOTES="&lt;p&gt;Exported from Review Manager 4.3 Beta&lt;br&gt;Exported from Review Manager 4.2.7&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2011-03-25 16:15:57 +0000" NOTES_MODIFIED_BY="Ema Roque" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2011-03-25 17:26:26 +0100" MODIFIED_BY="Ema Roque">
<TITLE MODIFIED="2011-03-25 16:11:45 +0000" MODIFIED_BY="Ema Roque">Levodopa for the treatment of restless legs syndrome</TITLE>
<CONTACT MODIFIED="2011-03-25 17:26:26 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="C55B950C82E26AA20130726FC83DC6A4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Magdolna</FIRST_NAME><LAST_NAME>Hornyak</LAST_NAME><EMAIL_1>magdolna.hornyak@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49761270 5020</PHONE_1><FAX_1>+ 49 40 7612705013</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2011-03-25 17:26:26 +0100" MODIFIED_BY="Ema Roque"><PERSON ID="BF1BEF6F82E26AA200AED564B62CA8A8" ROLE="AUTHOR"><FIRST_NAME>Hanna</FIRST_NAME><LAST_NAME>Scholz</LAST_NAME><EMAIL_1>hanna.scholz@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 761270 5357</PHONE_1></ADDRESS></PERSON><PERSON ID="04300295689766803046110120023521" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Claudia</FIRST_NAME><LAST_NAME>Trenkwalder</LAST_NAME><EMAIL_1>trenkwalder@pk-mx.de</EMAIL_1><ADDRESS><ORGANISATION>Paracelsus - Elena Hospital, Centre of Parkinson and Movement Disorders</ORGANISATION><ADDRESS_1>Klinikstrasse 16</ADDRESS_1><CITY>Kassel</CITY><ZIP>34128</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="67466654987436394892110120023942" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Ralf</FIRST_NAME><LAST_NAME>Kohnen</LAST_NAME><EMAIL_1>rkohnen@rpsweb.com</EMAIL_1><ADDRESS><ORGANISATION>RPS Research Germany GmbH, Nuremberg and University Erlangen-Nuremberg</ORGANISATION><ADDRESS_1>Scheurlstrasse 21</ADDRESS_1><CITY>Nürnberg</CITY><ZIP>90478</ZIP><COUNTRY CODE="DE">Germany</COUNTRY></ADDRESS></PERSON><PERSON ID="C55EFE5082E26AA20130726F0964539D" ROLE="AUTHOR"><FIRST_NAME>Levente</FIRST_NAME><LAST_NAME>Kriston</LAST_NAME><EMAIL_1>l.kriston@uke.uni-hamburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Medical Psychology</DEPARTMENT><ORGANISATION>University Medical Center, Hamburg - Eppendorf</ORGANISATION><ADDRESS_1>Martinistrasse 52</ADDRESS_1><CITY>Hamburg</CITY><ZIP>20246</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><FAX_1>+ 49 40 7410 54965</FAX_1></ADDRESS></PERSON><PERSON ID="C5538C8982E26AA20130726F753B6574" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Dieter</FIRST_NAME><LAST_NAME>Riemann</LAST_NAME><EMAIL_1>Dieter_Riemann@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry and Psychotherapy</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Hauptstrasse 5</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79104</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+497612706919</PHONE_1><FAX_1>+497612706619</FAX_1></ADDRESS></PERSON><PERSON ID="C55B950C82E26AA20130726FC83DC6A4" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Magdolna</FIRST_NAME><LAST_NAME>Hornyak</LAST_NAME><EMAIL_1>magdolna.hornyak@uniklinik-freiburg.de</EMAIL_1><ADDRESS><DEPARTMENT>Interdisciplinary Pain Canter</DEPARTMENT><ORGANISATION>University Medical Center, Freiburg</ORGANISATION><ADDRESS_1>Breisacher Strasse, 64</ADDRESS_1><CITY>Freiburg</CITY><ZIP>79106</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49761270 5020</PHONE_1><FAX_1>+ 49 40 7612705013</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2011-03-25 16:11:45 +0000" MODIFIED_BY="Ema Roque">
<UP_TO_DATE>
<DATE DAY="19" MONTH="1" YEAR="2011"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="12" YEAR="2008"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="20" MONTH="11" YEAR="2005"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="2005"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2011"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2011"/>
</DATES>
<WHATS_NEW/>
<HISTORY/>
<SOURCES_OF_SUPPORT MODIFIED="2010-05-21 13:19:02 +0100" MODIFIED_BY="[Empty name]">
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES MODIFIED="2010-05-21 13:19:02 +0100" MODIFIED_BY="[Empty name]">
<SOURCE MODIFIED="2010-05-21 13:19:02 +0100" MODIFIED_BY="[Empty name]">
<NAME>BMBF</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>Grant from the German Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung - BMBF, grant number DLR 01KG0723)</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2011-01-14 11:32:01 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2011-01-14 11:31:01 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-06-02 11:56:16 +0100" MODIFIED_BY="[Empty name]">Levodopa for restless legs syndrome</TITLE>
<SUMMARY_BODY MODIFIED="2011-01-14 11:31:01 +0000" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a common neurological disorder characterised by a nocturnal urge to move the legs that is usually associated with unpleasant sensations in the legs. Symptoms occur predominantly during rest, in the evening, and at night. Sleep disturbances are usually the reason why patients seek medical advice. The disorder is generally considered to be a chronic condition. Levodopa is recommended for the treatment of RLS. </P>
<P>We could include nine trials in the meta-analysis which compared levodopa treatment to placebo or to other active treatments in RLS and varied from one to eight weeks. Patients suffered from moderate to severe RLS and were treated with doses of 100 mg levodopa/25 mg dopamine decarboxylase up to 400 mg levodopa/100 mg dopamine decarboxylase. The studies were performed in European and Northern American countries.</P>
<P>Levodopa reduced symptom severity to a larger extent than placebo. Also clinicians rated RLS symptoms as more improved with levodopa than placebo. Periodic limb movements in sleep, monitored during polysomnography, were reduced more in levodopa treatment compared to placebo; however, total sleep time was not changed. Self rated quality of sleep and quality of life were markedly improved. Only a very low number of patients discontinued treatment due to adverse events but a larger number of patients on levodopa treatment reported adverse events compared to placebo. Evidence of three active controlled trials comparing levodopa to cabergoline, pergolide, and pramipexole was in favour of dopamine agonists regarding reduction of RLS severity (IRLS questionnaire), symptom improvement (CGI), and quality of life. The results of the other five endpoints do not favour any one treatment over another. However, due to a large range of confidence intervals in these few trials, superiority of one agent cannot be ruled out. </P>
<P>A serious adverse event developing during long-term dopaminergic medication, the so-called augmentation, is characterised by an earlier onset of symptoms during the day, faster onset of symptoms when at rest, spreading of symptoms to the upper limbs and trunk, and shorter duration of the treatment effect. Augmentation was not systematically assessed in most of the previous clinical studies. Future trials with longer treatment duration and with comparison to other treatment options are needed to investigate the occurrence of augmentation and the efficacy of levodopa treatment in RLS.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2011-01-14 11:30:56 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2010-06-02 11:55:03 +0100" MODIFIED_BY="[Empty name]">
<P>Levodopa plus dopamine decarboxylase inhibitor is a common treatment for restless legs syndrome (RLS).</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2011-01-13 13:08:18 +0000" MODIFIED_BY="[Empty name]">
<P>To evaluate efficacy and safety of levodopa for RLS compared to placebo and other active agents.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-11-30 15:48:17 +0000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL (<I>The Cochrane Library</I> 2008, Issue 4), MEDLINE, EMBASE, PsycINFO and CINAHL, from January 1985 to December 2008, reference lists of articles, and contacted pharmaceutical companies.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-11-30 15:29:49 +0000" MODIFIED_BY="[Empty name]">
<P>We included double-blind randomised controlled trials (RCT) investigating levodopa treatment versus placebo or other treatment for at least seven days in patients with RLS (age &#8805; 18 years). Outcomes included symptom severity, CGI-I, objective as well as self rated sleep parameters, quality of life, and safety parameters.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2011-01-13 13:07:38 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors extracted data, assessed risk of bias, and contacted pharmaceutical companies and authors for additional information. We collected dropouts due to adverse events and patients experiencing adverse events.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2011-01-14 11:30:56 +0000" MODIFIED_BY="[Empty name]">
<P>Six placebo controlled and three active controlled RCTs were included (521 participants). Symptom severity (11 point rating scale, 0 points indicating no symptoms, 10 points indicating maximally severe symptoms) was more reduced with levodopa than placebo in two studies (mean difference (MD) -1.34, 95% confidence interval (CI) -2.18 to -0.5, P = 0.002). Periodic limb movements in sleep per hour of sleep (PLMS-Index; PLMSI) improved by -26.28/h compared to placebo (95% CI -30.53 to -22.02, P &lt; 0.00001).The CGI-I changed more with levodopa than placebo in two studies (MD -1.25, 95% CI -1.89 to -0.62, P = 0.0001). In two studies, sleep quality (sleep questionnaire, visual analogue scale) showed a large effect (standardised mean difference (SMD) 0.92, 95% CI 0.52 to 1.33, P &lt; 0.00001) whereas quality of life (50 mm Visual Analogue Scales) improved by 3.23 compared to placebo (95% CI 1.64 to 4.82, P &lt; 0.0001). Few patients dropped out of treatment (3 of 218 patients) but more levodopa treated patients experienced adverse events than with placebo (odds ratio 2.61, 95% CI 1.35 to 5.04, P = 0.004). Two dopamine agonist controlled studies showed smaller effects with levodopa than cabergoline and pramipexole on the IRLS (MD 5.25, 95% CI 2.10 to 8.40, P =0.001), CGI-I (MD 0.62, 95% CI 0.37 to 0.87, P &lt; 0.00001), and quality of life (MD 5.54, 95% CI 2.65 to 8.43, P = 0.0002).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2011-01-13 13:14:35 +0000" MODIFIED_BY="[Empty name]">
<P>Levodopa is efficacious for the short-term treatment of RLS. Augmentation, the clinically most relevant adverse event, was not investigated sufficiently.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2011-01-14 11:32:01 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2011-01-14 10:15:26 +0000" MODIFIED_BY="[Empty name]">
<CONDITION MODIFIED="2011-01-14 10:14:43 +0000" MODIFIED_BY="[Empty name]">
<P>Restless legs syndrome (RLS) is a common neurological disorder with a high impact on sleep. RLS was first described in detail by <LINK REF="REF-Ekbom-1945" TYPE="REFERENCE">Ekbom 1945</LINK>. Obligatory diagnosis criteria were established by the International Restless Legs Syndrome Study Group (IRLSSG, <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>). These criteria were revised at a consensus conference held at the National Institute of Health (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). The essential criteria, supportive criteria and associated features of the disease are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>.</P>
<TABLE COLS="1" ROWS="4">
<TR>
<TD>
<P>
<B>Essential criteria</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).</P>
<P>2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.</P>
<P>3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</P>
<P>4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been present previously).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Supportive criteria and associated features of RLS</B>
</P>
</TD>
</TR>
<TR>
<TD>
<UL>
<LI>Positive family history</LI>
<LI>Response to dopaminergic therapy</LI>
<LI>Periodic limb movements (during wakefulness or sleep)</LI>
<LI>Natural clinical course</LI>
<LI>Sleep disturbance</LI>
</UL>
</TD>
</TR>
</TABLE>
<P/>
<P>Epidemiological surveys in Western Europe and in the USA indicate that up to 10% of the population are afflicted with RLS. The prevalence increases with age and is in females twice as high as in males (<LINK REF="REF-Berger-2004" TYPE="REFERENCE">Berger 2004</LINK>; <LINK REF="REF-Berger-2007" TYPE="REFERENCE">Berger 2007</LINK>; <LINK REF="REF-H_x00f6_gl-2003" TYPE="REFERENCE">Högl 2003</LINK>; <LINK REF="REF-Phillips-2000" TYPE="REFERENCE">Phillips 2000</LINK>; <LINK REF="REF-Rothdach-2000" TYPE="REFERENCE">Rothdach 2000</LINK>; <LINK REF="REF-Ulfberg-2001" TYPE="REFERENCE">Ulfberg 2001</LINK>). Approximately one third of the persons reporting RLS symptoms (i.e. 2% to 3% of the population) may be in need of medical treatment (<LINK REF="REF-Happe-2008" TYPE="REFERENCE">Happe 2008</LINK>).</P>
<P>Supporting features of the syndrome include periodic leg movements while awake (PLMW) and during sleep (PLMS), both are recorded in polysomnography (PSG). In PLMS monitoring a bilateral surface electromyogram of the anterior tibial muscles is recorded. Scoring of PLMS is made according to standard criteria (<LINK REF="REF-Bonnet-1993" TYPE="REFERENCE">Bonnet 1993</LINK>; <LINK REF="REF-Iber-2007" TYPE="REFERENCE">Iber 2007</LINK>; <LINK REF="REF-Zucconi-2006" TYPE="REFERENCE">Zucconi 2006</LINK>). PLMS occur frequently in several sleep disorders other than RLS and may also be present in subjects who do not complain about sleep disturbance. However, PLMS are seen more frequently in patients with RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Hornyak-2004" TYPE="REFERENCE">Hornyak 2004</LINK>). Although the presence of PLMS is not specific to RLS, an elevated PLMS index (&gt; 15 PLMS per hour of sleep; PLMSI; <LINK REF="REF-American-Academy-of-Sleep-Medicine-2005" TYPE="REFERENCE">American Academy of Sleep Medicine 2005</LINK>) is supportive of the diagnosis of RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). The family history for the disorder is positive in 40% to 60% of cases. RLS is a polygenetic disorder; linkage studies in families with RLS revealed several loci but have not yet identified disease-causing sequence variants (<LINK REF="REF-Stefansson-2007" TYPE="REFERENCE">Stefansson 2007</LINK>; <LINK REF="REF-Winkelmann-2007" TYPE="REFERENCE">Winkelmann 2007</LINK>). Generally, patients with positive family history experience an earlier onset of symptoms (before the age of 45 years) than patients without afflicted relatives. A positive response to levodopa also supports the diagnosis of RLS, with almost 90% patients showing a 50% relief of symptoms when treated with this agent (<LINK REF="REF-Stiasny_x002d_Kolster-2006" TYPE="REFERENCE">Stiasny-Kolster 2006</LINK>).</P>
<P>Sleep disturbances are a commonly associated feature of the disorder and are usually the reason why patients seek medical advice (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). However, patients with milder forms of RLS may not report on disturbed sleep, therefore, sleep disturbance is not considered to be necessary for, or supportive of the diagnosis of RLS (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>). In patients who seek treatment, typically, the severity and frequency of symptoms increase over time. Thus, the disorder is generally considered to be a chronic condition. Neurological examinations usually result in unremarkable findings for patients with idiopathic (primary) RLS. Secondary forms of the disorder, however, have to be identified, and factors that may exacerbate or trigger symptoms have to be treated. Beside the established causes of secondary RLS (e.g. end-stage renal disease, pregnancy, and iron deficiency), an increasing number of conditions seems to be associated with the disorder (<LINK REF="REF-Allen-2007" TYPE="REFERENCE">Allen 2007</LINK>; <LINK REF="REF-Connor-2008" TYPE="REFERENCE">Connor 2008</LINK>; <LINK REF="REF-Manconi-2004" TYPE="REFERENCE">Manconi 2004</LINK>; <LINK REF="REF-Sch_x00f6_ls-1998" TYPE="REFERENCE">Schöls 1998</LINK>; <LINK REF="REF-Walters-2007" TYPE="REFERENCE">Walters 2007</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2011-01-14 10:15:26 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment focuses on the relief of limb symptoms and on the sequelae of the disorder such as disturbed sleep and consequent daytime sleepiness and impaired quality of life (<LINK REF="REF-Kushida-2007" TYPE="REFERENCE">Kushida 2007</LINK>; <LINK REF="REF-Talati-2009" TYPE="REFERENCE">Talati 2009</LINK>).</P>
<P>Since the 1980s, therapy has focused on levodopa and dopamine agonists (<LINK REF="REF-Stiasny_x002d_Kolster-2009" TYPE="REFERENCE">Stiasny-Kolster 2009</LINK>; <LINK REF="REF-Trenkwalder-2008" TYPE="REFERENCE">Trenkwalder 2008</LINK>). Levodopa was the first dopaminergic substance that was investigated for the treatment of RLS. The very first report on positive effects of levodopa (plus benserazide) on RLS was published by <LINK REF="REF-Akpinar-1982" TYPE="REFERENCE">Akpinar 1982</LINK>. Clinical research on treatment was boosted by the definition of diagnostic criteria (<LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>) and by the development of severity rating scales.  </P>
<P>Since then, several studies have examined the efficacy of dopaminergic substances in RLS. However, only a few studies have examined treatment effects longer than 12 weeks and no study has examined long-term effects (i.e. longer than one year). Levodopa trials were conducted mainly in the 1990s using a cross-over design with few included patients; only one large scale multi-centre trial is available. Clinical experience revealed the most serious side effect of dopaminergic treatment, the development of augmentation, which was first described by <LINK REF="REF-Allen-1996" TYPE="REFERENCE">Allen 1996</LINK>. Augmentation is characterised by an overall increase in severity of RLS symptoms that can be seen in an earlier onset of symptoms during the day, faster onset of symptoms when at rest, spreading of symptoms to the upper limbs and trunk, and shorter duration of the treatment effect (<LINK REF="REF-Garcia_x002d_Borreguero-2007a" TYPE="REFERENCE">Garcia-Borreguero 2007a</LINK>).</P>
<P>Augmentation as a side effect in RLS treatment was prospectively and systematically evaluated only in one actively controlled levodopa trial and a few dopamine agonist trials, currently not yet published. Previous data on frequency and severity of augmentation vary widely, clinical experience shows that augmentation may occur more frequently during levodopa treatment than during treatment with dopamine agonists (<LINK REF="REF-Garcia_x002d_Borreguero-2007b" TYPE="REFERENCE">Garcia-Borreguero 2007b</LINK>). Therefore, levodopa is only recommended in RLS patients with intermittent symptoms or as initial treatment option according to recent treatment guidelines. In case of continuous treatment, the daily dosage of levodopa should not exceed 200 mg to 300 mg. Dopamine agonists are considered first-line treatment of RLS (<LINK REF="REF-Oertel-2007" TYPE="REFERENCE">Oertel 2007</LINK>; <LINK REF="REF-Trenkwalder-2005" TYPE="REFERENCE">Trenkwalder 2005</LINK>).</P>
<P>Alternative treatment options in RLS other than dopaminergic drugs include antiepileptics such as gabapentine, gabapentin enacarbil and valproic acid, as well as pregabalin and opioids (<LINK REF="REF-Conti-2008" TYPE="REFERENCE">Conti 2008</LINK>; <LINK REF="REF-Eisensehr-2004" TYPE="REFERENCE">Eisensehr 2004</LINK>; <LINK REF="REF-Garcia_x002d_Borreguero-2002" TYPE="REFERENCE">Garcia-Borreguero 2002</LINK>; <LINK REF="REF-Kushida-2009" TYPE="REFERENCE">Kushida 2009</LINK>; <LINK REF="REF-Trenkwalder-2008" TYPE="REFERENCE">Trenkwalder 2008</LINK>; <LINK REF="REF-Walters-1993" TYPE="REFERENCE">Walters 1993</LINK>). However, to date, the number of studies investigating substances other than dopaminergic drugs is still limited.</P>
<P>All previous trials investigated the symptomatic therapy of RLS. No cure of RLS has been proposed except when treating causes of secondary RLS such as iron deficiency.</P>
<P>Recently, a few meta-analyses and reports have been undertaken to summarise evidenced based therapies in RLS (<LINK REF="REF-Baker-2008" TYPE="REFERENCE">Baker 2008</LINK>; <LINK REF="REF-Conti-2007" TYPE="REFERENCE">Conti 2007</LINK>; <LINK REF="REF-Hansen-2009" TYPE="REFERENCE">Hansen 2009</LINK>; <LINK REF="REF-Quilici-2008" TYPE="REFERENCE">Quilici 2008</LINK>; <LINK REF="REF-Trenkwalder-2008" TYPE="REFERENCE">Trenkwalder 2008</LINK>; <LINK REF="REF-Zintzaras-2010" TYPE="REFERENCE">Zintzaras 2010</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-11-30 15:31:37 +0000" MODIFIED_BY="[Empty name]">
<P>The aetiology of the disorder is not sufficiently understood. It is generally accepted that a dysfunction of the central nervous dopaminergic system may be responsible (<LINK REF="REF-Hening-2004" TYPE="REFERENCE">Hening 2004</LINK>; <LINK REF="REF-Trenkwalder-2004" TYPE="REFERENCE">Trenkwalder 2004</LINK>). The involvement of the dopaminergic system is supported by the effectiveness of dopaminergic drugs for the disorder, at least in those phenotypes which benefit from dopaminergic treatment (<LINK REF="REF-Trenkwalder-2010" TYPE="REFERENCE">Trenkwalder 2010</LINK>). There is no consistent evidence from neuroimaging studies of how a dopaminergic drug might work in RLS. Newest research indicates a significant decrease of D2 receptor density in the putamen of RLS patients (<LINK REF="REF-Connor-2009" TYPE="REFERENCE">Connor 2009</LINK>). Brain iron storage may be involved in many phenotypes of RLS. Currently, it seems that supplying iron is both a symptomatic and in some cases, i.e. in pregnancy and iron deficiency anaemia, a curative way of treating RLS - although the mechanism of low brain iron in RLS is not yet known. Other curative treatments for idiopathic RLS are not known.</P>
</THEORY>
<IMPORTANCE MODIFIED="2011-01-13 14:14:12 +0000" MODIFIED_BY="[Empty name]">
<P>Recently, one review has described efficacy and safety of levodopa treatment for RLS including evaluation of polysomnography. However, clinically relevant outcomes such as severity of the disorder, quality of sleep, and quality of life were not evaluated in placebo or active controlled studies (<LINK REF="REF-Conti-2007" TYPE="REFERENCE">Conti 2007</LINK>).</P>
<P>We undertook the present evaluation to systematically assess the therapeutic efficacy and safety of levodopa treatment in RLS. According to a pre-reviewed protocol, we searched several databases, assessed study quality using a predefined quality assessment, and evaluated a wide range of clinically relevant aspects of treatment effects. We aimed to evaluate the therapeutic efficacy of levodopa treatment for RLS as assessed by self rated symptom severity scales and PSG parameters such as PLMSI and total sleep time. Comprehensive analyses included questionnaires of global improvement, quality of sleep, quality of life, and safety parameters such as patients dropping out of treatment as well as experience of adverse events.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-06-02 11:58:24 +0100" MODIFIED_BY="[Empty name]">
<P>To evaluate the efficacy and safety of levodopa in comparison to placebo and other agents for patients with RLS.</P>
</OBJECTIVES>
<METHODS MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2011-01-13 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2010-06-02 11:58:30 +0100" MODIFIED_BY="[Empty name]">
<P>We included double-blind and randomised controlled trials (RCTs) investigating the treatment of RLS with levodopa versus placebo or another drug, enclosing parallel group trials as well as cross-over trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2011-01-13 14:15:20 +0000" MODIFIED_BY="[Empty name]">
<P>Adult patients (18 years or more) had to have a diagnosis of primary or secondary RLS according to diagnosis criteria of the IRLSSG (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>). Studies conducted before 1995 (i.e. before standardising diagnostic criteria; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>) had to present explicitly predefined diagnostic criteria for inclusion in the meta-analyses.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-11-30 15:31:44 +0000" MODIFIED_BY="[Empty name]">
<P>The experimental intervention consisted of any dose or regimen of levodopa with carbidopa or benserazide in any method of administration (oral, intravenous or transdermal, regular release, and sustained-release) for a minimum of seven days. In the control intervention, either placebo or other comparative drugs were used.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2011-01-13 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<P>Divided into primary and secondary endpoints, we evaluated the following endpoints:</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2011-01-13 14:16:22 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Symptoms of RLS experienced subjectively by the patient and assessed with validated instruments (self rated questionnaires assessing severity of symptoms)</LI>
<LI>PLMS Index (number of PLMS per hour of total sleep time or time in bed)</LI>
<LI>Total sleep time (min)</LI>
<LI>Number of dropouts due to adverse events (safety parameter)</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2011-01-13 14:16:41 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Clinical Global Impressions - Improvement (CGI-I)</LI>
<LI>Self rated quality of sleep (description of the included questionnaires, see below)</LI>
<LI>Quality of life (description of the included questionnaires, see below)</LI>
</OL>
<SUBSECTION>
<HEADING LEVEL="5">Additional outcomes which were expected to be useful for explaining effects:</HEADING>
<OL>
<LI>Number of patients experiencing adverse events (safety parameter)</LI>
<LI>Number of patients experiencing augmentation (safety parameter)</LI>
</OL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-11-30 15:32:15 +0000" MODIFIED_BY="[Empty name]">
<P>We used the following resources for identification of relevant studies in any language.</P>
<ELECTRONIC_SEARCHES MODIFIED="2010-11-30 15:32:07 +0000" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, <I>The Cochrane Library </I>2008, Issue 4), MEDLINE (1985 to 2008), EMBASE (1985 to 2008), PsycINFO (1985 to 2008), and CINAHL (1985 to 2008). We did not search the Cochrane Movement Disorders Group's trials register as this database had not been updated by the Cochrane Movement Disorders Group. The respective search strategies are displayed in the <LINK TAG="APPENDICES" TYPE="SECTION">Appendices</LINK>.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-11-30 15:32:15 +0000" MODIFIED_BY="[Empty name]">
<P>We searched online databases for additional unpublished studies such as the Internet sites <A HREF="http://www.clinicaltrials.gov">www.clinicaltrials.gov</A> and <A HREF="http://www.clinicalstudyresults.org">www.clinicalstudyresults.org</A>. <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> lists numbers of studies retrieved in these searches. We checked recent reviews and the references of all included studies for further, potentially relevant publications in any language. We contacted the responsible pharmaceutical company for published and unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2010-11-30 15:32:28 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (HS and MH, the latter with support of CL, see acknowledgments) reviewed independently titles and abstracts of all obtained publications to assess their potential relevance. Subsequently, we assessed the potentially relevant publications for inclusion from the full text. Authorship and results were not blinded. In both steps, we resolved disagreements by discussion.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2011-01-13 14:20:06 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (HS and MH, the latter with support of CL) independently extracted data using a predefined form. We resolved disagreements and errors. Extraction included diagnostic criteria, study type, numbers of patients, doses given and procedures of titration, age, gender, ethnicity, country of trial, treatment duration, occurrence of adverse events and withdrawals due to adverse events.</P>
<P>All questionnaires used in the included studies are presented in <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK>.</P>
<P>RLS severity was assessed by a visual analogue scale (VAS, 0-10), a 11-point rating scale, and the IRLS scale (<LINK REF="REF-Walters-2003" TYPE="REFERENCE">Walters 2003</LINK>). The IRLS is a validated severity rating scale with 10 items rated from 0 to 4 and a total score of 0 to 40. Scores of 1 to 10 represent mild, 11 to 20 moderate, 21 to 30 severe and 31 to 40 points indicate very severe symptoms (<LINK REF="REF-Walters-2003" TYPE="REFERENCE">Walters 2003</LINK>). Total sleep time in minutes and the index of periodic limb movements (PLM) per hour of total sleep time (PLMSI) were assessed polysomnographically. One study reported the PLM index, i.e. PLMs per hour of time in bed (PLMI). We extracted observer rated improvement using the Clinical Global Impressions - Improvement (CGI-I; <LINK REF="REF-National-Institute-of-Mental-Health-1976" TYPE="REFERENCE">National Institute of Mental Health 1976</LINK>). Self rated sleep quality included the scale &#8220;quality of sleep&#8221; of the questionnaire Schlaffragebogen A (SF-A; <LINK REF="REF-Goertelmeyer-1985" TYPE="REFERENCE">Goertelmeyer 1985</LINK>), the scale &#8220;satisfaction with sleep&#8221; of the RLS-6 scales (<LINK REF="REF-Kohnen-2004" TYPE="REFERENCE">Kohnen 2004</LINK>) and VAS. We extracted data on VAS and the disease-specific QoL-RLS by <LINK REF="REF-Kohnen-2002" TYPE="REFERENCE">Kohnen 2002</LINK> in order to evaluate quality of life. Safety parameters included dropout rates due to adverse events and number of patients experiencing adverse events.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>Two authors (HS and MH, the latter with support of CL) independently performed assessment of methodological quality using The Cochrane Collaboration's tool for assessing bias (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 8). We classified criteria like randomisation, allocation concealment, blinding, incomplete outcome data, and selective outcome reporting in each trial indicating the likelihood of risk of bias (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>). We resolved any resulting disagreements by discussion. The results of the assessment of risk of bias are displayed in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> section for each trial as well as in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2011-01-14 10:16:16 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>We analysed safety parameters such as dropout rates due to adverse events and patients experiencing adverse events during treatment using odds ratios with 95% confidence intervals. Odds ratios above 1 indicate more negative events with levodopa compared to negative events with placebo or other dopamine agonists.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>We analysed continuous data with the inverse variance method implementing mean differences and standard errors for the outcomes severity of RLS, PLMSI, total sleep time, CGI-I, and quality of life. All effect estimates include a 95% confidence interval. Quality of sleep was investigated on two different scales. Therefore, we used the inverse variance method implementing standardised mean differences, i.e. Hedges' adjusted g, with standard errors and a confidence interval of 95%. Effects include values such as 0.2 representing a small effect, 0.5 representing a moderate effect, and 0.8 indicating a large effect (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). Negative mean differences indicate better response in the treatment group for severity of RLS, PLMSI and CGI-I, positive values indicate better response in the treatment group for total sleep time, quality of sleep and quality of life. Active controlled trials were also pooled using the inverse variance method.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2011-01-14 10:17:20 +0000" MODIFIED_BY="[Empty name]">
<P>Eight of the nine included trials were cross-over trials. Four studies provided sufficient information to perform analyses on dependent measures. The other four studies had to be analysed using independent procedures. In three trials, levodopa was compared to another active drug, that is cabergoline, pergolide, and pramipexole.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-11-30 15:33:35 +0000" MODIFIED_BY="[Empty name]">
<P>We extracted end of treatment means or mean changes from baseline and standard deviations or standard errors from the primary analysis population, which consisted of eight of nine trials of patients fulfilling the protocol. We contacted the pharmaceutical companies Hoffmann La-Roche, Pfizer, and Boehringer Ingelheim for further information on the supported studies. We also contacted authors of the studies <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>, <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>, <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK> and <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK> for missing data, but unfortunately, we could not obtain further information from the contacted authors.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<P>We tested heterogeneity of studies with Chi² tests. Additionally presented I² statistics give an estimate of the degree of heterogeneity between studies. Percentages of 0% to 40% represent low, 30% to 60% moderate, 50% to 90% substantial, and 75% to 100% indicate considerable heterogeneity (<LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 9).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-06-02 12:02:10 +0100" MODIFIED_BY="[Empty name]">
<P>To identify possible publication bias we visually inspected funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-01-14 10:12:42 +0000" MODIFIED_BY="[Empty name]">
<P>Random-effects models were used to calculate effect sizes as no common underlying effect could be expected due to the diversity of study populations and medications. As we could consider the cross-over design in four placebo controlled studies contributing data to all endpoints, we used the generic inverse variance input method for all continuous outcomes. We used the inverse variance method for continuous outcomes of the active controlled studies. We analysed dichotomous outcomes in all meta-analyses using odds ratios with the Mantel-Haenszel method.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-06-02 12:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>We performed separate meta-analyses on results of placebo controlled studies and on results of active controlled studies. </P>
</SUBGROUP_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2011-01-14 11:31:29 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2011-01-14 10:24:07 +0000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2011-01-14 10:23:15 +0000" MODIFIED_BY="[Empty name]">
<P>Our searches generated 302 publications by searching the electronic databases. Of these, we excluded 279 after screening of titles and abstracts as they were mostly overviews or publications on other aspects of RLS. Of the remaining 23 publications, eight studies could be included after inspection of full texts. A search of online databases yielded one additional trial.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2011-01-14 10:24:07 +0000" MODIFIED_BY="[Empty name]">
<P>Nine randomised, controlled, and double-blind studies were included in this review comprising a total of 521 patients with five to 32 patients in six placebo controlled trials (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>) and 11 to 361 patients in three active controlled trials (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>). The trials were actively controlled with the dopamine agonists cabergoline (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), pergolide (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>), and pramipexole (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>). All trials except <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK> were cross-over trials.</P>
<P>Methods, included patients, interventions, and relevant outcomes of all included trials are described in the <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Setting</HEADING>
<P>Six of the nine trials were performed in single centres. Patients were recruited from outpatient clinic settings. Studies were conducted in Germany (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), Canada (<LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>), Switzerland (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>), and Turkey (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>).</P>
<P>Treatment durations varied between seven days in one study (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>), 14 to 16 days in three trials (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>) and three to four weeks in four studies (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>). One actively controlled study investigated treatment effects after eight and 30 weeks (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>). Treatment effects after eight weeks were included in the meta-analyses in order to be able to compare these data to other trial results. Mean duration of the included studies was 23.6 days (SD 14.3).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Patients</HEADING>
<P>All patients had symptoms of RLS which were assessed according to the criteria defined by the IRLSSG (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>) in five studies (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>). In four trials, patients were assessed similarly to these diagnostic criteria (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>).</P>
<P>In five studies, patients had a diagnosis of primary RLS. Two studies included patients with primary and secondary RLS (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>). One study only investigated patients with secondary RLS (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>). In one trial, no information was given (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>).</P>
<P>Age was similarly distributed in all trials with a mean of 57.2 years, ranging from 49.6 years (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>) to 68.2 years (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>). Mean percentage of included female patients was 57.1%, ranging from 35.7% (<LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>) to 80% (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Interventions</HEADING>
<P>Study drugs were given orally once daily (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), twice daily (<LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>) and in controlled or dual-release form (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>).</P>
<P>Levodopa was given together with the dopamine decarboxylase inhibitor (DDC) benserazide in seven trials (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>) and with carbidopa in two studies (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>). A fixed dose of 100 mg levodopa/25 mg carbidopa was given in one trial (<LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>) and 200 mg levodopa/50 mg benserazide in three trials (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>). In five studies flexible uptitration from 100 mg levodopa/25 mg benserazide or carbidopa to either 200 mg/50 mg (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>), 300 mg/75 mg (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>; <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>), or 400 mg/100 mg (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>) was used. In four of eight cross-over studies, medication washout periods between the first and the second treatment were not reported or not used (<LINK REF="STD-Akpinar-1987" TYPE="STUDY">Akpinar 1987</LINK>; <LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>).</P>
<P>In the active controlled trials cabergoline was uptitrated to a fixed dose of 2.0 mg which could be increased to 3.0 mg (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>). Pergolide was flexibly uptitrated from 0.125 mg to 0.25 mg (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>) and pramipexole was flexibly uptitrated from 0.25 mg to 0.75 mg (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>Self rated assessments included symptoms of severity and symptom improvement as well as self rated quality of sleep and quality of life. Quality of sleep was additionally investigated using polysomnography. Lastly, studies included safety assessment.</P>
</SUBSECTION>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-11-30 15:36:05 +0000" MODIFIED_BY="[Empty name]">
<P>Fifteen publications were excluded while we screened the full texts. In two trials, only a part of the investigated population had a diagnosis of RLS. Three trials had study durations of less than seven days. Open label designs and inadequate control group designs were used in five trials. Duplicate information from conference proceedings published later was found five times. See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> for details.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-11-30 15:36:29 +0000" MODIFIED_BY="[Empty name]">
<ALLOCATION MODIFIED="2010-11-30 15:36:10 +0000" MODIFIED_BY="[Empty name]">
<P>Randomisation procedure remained unclear in five studies, the four other studies reported computer-generated randomisation lists. Allocation of treatment was reported in five studies with allocation of identical, numbered packages assigned to patients.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-06-02 12:04:31 +0100" MODIFIED_BY="[Empty name]">
<P>Blinding of participants, investigators and data analysts was sufficiently described in six trials. Blinded polysomnography rating was reported only in one study, six other studies gave insufficient information.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-06-02 13:10:55 +0100" MODIFIED_BY="[Empty name]">
<P>Three studies with premature withdrawals reported dropouts and reasons for these. All studies except one (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>) investigated polysomnography parameters, data analyses of these were based on per protocol population.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-06-02 12:04:40 +0100" MODIFIED_BY="[Empty name]">
<P>Studies investigated a range of endpoints such as symptom severity, quality of sleep, quality of life and safety parameters. In one study, not all implemented measures were reported fully in the trial publication. In another study, no endpoints had been specified beforehand in the trial publication.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-11-30 15:36:29 +0000" MODIFIED_BY="[Empty name]">
<P>Two studies were supported by government grants, five studies were sponsored by pharmaceutical companies, two studies did not report on funding. Several studies that used levodopa as the active comparator were sponsored by companies who aimed to licence the comparative substance i.e. a dopamine agonist (<LINK REF="STD-BI-2006" TYPE="STUDY">BI 2006</LINK>) and used equivalent dosages of levodopa taken from trials in Parkinson disease. Equivalent dosages of dopaminergic substances are not available for RLS patients.</P>
<P>We could not ascertain any other major source of bias.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2011-01-14 11:31:29 +0000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Comparison I: Levodopa versus placebo</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1) Change in symptoms on severity scales</HEADING>
<P>Two studies reported severity ratings of RLS symptoms during the past 24 hours or during the night ranging from 0 to 10 (10 = bad state). These studies were conducted before the IRLS was validated. Treatment doses were 146 mg/36.6 mg (<LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>) and 200 mg/50 mg levodopa/DDC (<LINK REF="STD-Eisensehr-2004" TYPE="STUDY">Eisensehr 2004</LINK>). The mean treatment difference (MD) of levodopa was -1.34 compared to placebo (95% CI -2.18 to -0.50, P = 0.002; I² = 0%, see <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2) Change in periodic limb movements in sleep index (PLMSI)</HEADING>
<P>Four trials reported results of PLM per hour of total sleep time, one study which applied an actigraphy method reported data of PLM per time in bed (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>). Mean doses ranged from 100 mg/25 mg to 200 mg/50 mg levodopa/DDC. Mean difference between levodopa and placebo was -26.28/h favouring levodopa (95% CI -30.53 to -22.02, P &lt; 0.00001; I² = 4%, see <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3) Change in total sleep time</HEADING>
<P>Patients receiving levodopa did not differ statistically significantly from patients receiving placebo with regard to total sleep time in four trials (see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4) Number of dropouts due to adverse events</HEADING>
<P>Patients dropped out of active and placebo treatment only in two of six short term trials. Those two trials with doses of 146 mg/37 mg and 159 mg/40 mg levodopa/DDC showed no difference between levodopa and placebo treatment (see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5) Improvement on CGI-I</HEADING>
<P>Two trials reported data on CGI improvement. The scale ranges from 1 = very much better to 7 = very much worse. Levodopa doses were 146 mg/37 mg and 159 mg/40 mg levodopa/DDC. Treatment resulted in a -1.25 points lower rating compared to placebo treatment (95% CI -1.89 to -0.62, P = 0.0001, I² = 0%, see <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6) Change in self rated quality of sleep</HEADING>
<P>In two trials with mean treatment doses of 146 mg/37 mg and 159 mg/40 mg levodopa/DDC, quality of sleep improved more with levodopa compared to placebo treatment (standardised mean difference (SMD) 0.92, 95% CI 0.52 to 1.33, P &lt; 0.00001, I² = 0%, see <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7) Change in quality of life</HEADING>
<P>Quality of life improved more with levodopa compared to placebo treatment as shown in two trials with doses of 146 mg/37 mg and 159 mg/40 mg levodopa/DDC (MD 3.23, 95% CI 1.64 to 4.82, P &lt; 0.0001, I² = 0%, see <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">8) Number of patients experiencing adverse events</HEADING>
<P>In four of five included trials with doses ranging from 100 mg/25 mg to 200 mg/50 mg levodopa/DDC, patients experienced adverse events. In these trials, a higher number of patients experienced adverse events when treated with levodopa versus those treated with placebo (Odds Ratio (OR) 2.61, 95% CI 1.35 to 5.04, P = 0.004, I² = 0%, see <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
<P>Augmentation was not mentioned in seven trials and not reliably and comparably assessed in the remaining two trials. Therefore we could not perform meta-analysis on this outcome.</P>
<P> </P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Comparison II: Levodopa versus dopamine agonists</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1) Change on severity scale IRLS</HEADING>
<P>Changes on the IRLS were evaluated in two trials comparing cabergoline up to 3.0 mg or pramipexole up to 0.75 mg with levodopa up to 300 mg/75 mg levodopa/DDC. Reductions on the IRLS after treatment were smaller during levodopa treatment compared to dopamine agonist treatment with a mean difference of 5.25 (95% CI 2.1 to 8.4, P = 0.001) and moderate heterogeneity (I² = 55%). Cabergoline showed a quantitatively larger treatment difference from levodopa than pramipexole (see <LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2) Change in periodic limb movements per time in bed (PLMI)</HEADING>
<P>One trial investigated PLMI when treated with pramipexole up to 0.75 mg in comparison to levodopa up to 300 mg/75 mg levodopa/DDC. Effects on PLMI did not differ statistically significantly between the substances (MD 3.80/h, 95% CI -1.48 to 9.08; P = 0.16).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">3) Change in total sleep time</HEADING>
<P>In one study, treatment with levodopa (mean dose of 291 mg levodopa/DDC) tended to show a smaller increase of total sleep time compared to pergolide treatment (up to 0.25 mg; MD -76.00 min, 95% CI -155.82 to 3.82; P = 0.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">4) Number of dropouts due to adverse events</HEADING>
<P>Numbers of patients dropping out of treatment due to adverse events were slightly but not significantly lower with levodopa treatment (dose of levodopa up to 300 mg/75 mg levodopa/DDC) compared to patients treated with dopamine agonists (dose of cabergoline up to 3.0 mg or pramipexole up to 0.75 mg; OR 0.59, 95% CI 0.33 to 1.04, P = 0.07; see <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>). Whereas the cabergoline trial with the higher weight in the meta-analysis (weight: 96.9%) favoured levodopa, the pramipexole trial (weight: 3.1%) was in favour of pramipexole. The effect size of one trial investigating pergolide could not be estimated as no patients had dropped out of the study.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5) Improvement on CGI-I</HEADING>
<P>One trial reported data on CGI improvement ranging from 1 = very much better to 7 = very much worse. Treatment with levodopa up to 300 mg/75 mg levodopa/DDC revealed a smaller improvement compared to cabergoline treatment up to 3.0 mg (MD 0.62; 95% CI 0.37 to 0.87, P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">5) Change in self rated quality of sleep</HEADING>
<P>One trial compared the change in self rated quality of sleep with cabergoline treatment up to 3.0 mg with levodopa treatment up to 300 mg/75 mg levodopa/DDC. Quality of sleep showed a tendency for larger improvement with cabergoline compared to levodopa after treatment but this change was not statistically significant (P = 0.09; see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">6) Change in disease-specific quality of life</HEADING>
<P>One trial investigated change in disease-specific quality of life in cabergoline treated patients (up to 3.0 mg) compared to levodopa (up to 300 mg/75 mg levodopa/DDC). A smaller improvement for treatment with levodopa compared to cabergoline was found (MD 5.54, 95% CI 2.65 to 8.43, P = 0.0002).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">7) Number of patients experiencing adverse events</HEADING>
<P>Three trials reported numbers of patients experiencing adverse events. Patients were treated with cabergoline, pergolide or pramipexole and compared to those treated with levodopa. Levodopa treated patients did not differ from patients treated with dopamine agonists regarding the experience of adverse events (OR 0.35, 95% CI 0.05 to 2.30, I² = 63%). The odds ratio was numerically but non-significantly larger when comparing levodopa treated patients (up to 300 mg/75 mg levodopa/DDC) to those treated with pramipexole (up to 0.75 mg; OR 3.08, 95% CI 0.12 to 77.91), indicating that slightly more levodopa treated patients experienced adverse events than pramipexole treated patients. Cabergoline and pergolide resulted in odds ratios below 1(up to 3.0 mg; OR 0.49, 95% CI 0.31 to 0.75 and up to 0.25 mg; OR 0.04, 95% CI 0.00 to 0.43 respectively) when comparing these to levodopa (300 mg/75 mg and 400 mg/100 mg levodopa/DDC). Hence, fewer levodopa treated patients experienced adverse events in these studies compared to cabergoline and pergolide (see <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>).</P>
<P>Experience of augmentation was not reliably and comparably assessed in the active controlled trials, therefore we could not perform meta-analysis on this outcome.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2011-01-14 11:32:01 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY_OF_RESULTS MODIFIED="2011-01-14 11:31:49 +0000" MODIFIED_BY="[Empty name]">
<P>Levodopa was superior to placebo treatment regarding improvement of RLS symptoms (presented as severity ratings and CGI-I), quality of sleep, and quality of life. The severity rating presented a decrease above the minimally important difference (<LINK REF="REF-Dworkin-2008" TYPE="REFERENCE">Dworkin 2008</LINK>). Self rated quality of sleep showed a large effect (<LINK REF="REF-Cohen-1988" TYPE="REFERENCE">Cohen 1988</LINK>). However, the results are limited owing to the low number of studies included (only two per outcome). The PLMSI showed markedly larger improvement with levodopa treatment whereas treatment effects of total sleep time did not differ from placebo treatment. Patients were not more likely to drop out of levodopa treatment due to adverse events but experienced more adverse events than placebo treated patients (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>).</P>
<P>Trials comparing levodopa to cabergoline, pergolide, and pramipexole showed lower effects with levodopa on the IRLS (cabergoline, pramipexole), the CGI-I (cabergoline), and quality of life (cabergoline). The mean treatment difference of the IRLS was above the non-inferiority margin of three points and close to six points which is regarded a difference of clinical relevance. A tendency of levodopa showing lower treatment effects was seen for total sleep time and self rated quality of sleep. There was a further trend of a lower dropout rate due to adverse events with levodopa treatment compared to active comparators. Heterogeneous evidence was present in numbers of levodopa treated patients with adverse events compared to those with other dopaminergic treatments. Also PLMI was not different in pramipexole versus levodopa treated patients. In these comparisons, it has also to be taken into account that all meta-analyses but those investigating safety parameters were based on one to two studies (see <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2011-01-14 10:27:51 +0000" MODIFIED_BY="[Empty name]">
<P>Patients were recruited from outpatient settings with moderate to severe RLS and represent the usual patient population requiring treatment. In five studies, diagnosis was made according to valid diagnostic criteria. The remaining studies were conducted before diagnostic criteria were published, but their description of RLS symptoms closely resembled the IRLS criteria.</P>
<P>Treatment durations varied between studies from one to eight weeks. Only one actively controlled trial also investigated treatment effects after 30 weeks. These are short time periods for the investigation of treatment effects; particularly since RLS is a chronic disease and medication only suppresses symptoms but does not cure the disorder. The lack of long-term studies is especially relevant for augmentation, which is the most important treatment complication in dopaminergic treatment but was only reported in one placebo controlled and one active controlled study. Augmentation usually develops during long-term treatment (<LINK REF="REF-Allen-2003" TYPE="REFERENCE">Allen 2003</LINK>; <LINK REF="REF-Trenkwalder-2008" TYPE="REFERENCE">Trenkwalder 2008</LINK>). Therefore, controlled long-term studies of at least 12 months duration are needed.</P>
<P>In summary, all relevant aspects of symptom severity and well being related improvements were assessed in at least some placebo and active controlled studies. Limiting factors for the validity of the results are the restricted number of studies, low numbers of included patients and short duration of trials.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2011-01-14 11:32:01 +0000" MODIFIED_BY="[Empty name]">
<P>We searched all relevant databases and public trial registers provided by the pharmaceutical companies and by government. Doing this, we could obtain published as well as unpublished trials. Pharmaceutical companies contributed additional data. Therefore, it seems unlikely that there are additional unpublished trials.</P>
<P>We retrieved six placebo controlled trials and three active controlled studies. Except for one large scale trial, all studies comprised very few patients. Two studies were conducted before the introduction of official diagnosis criteria in 1995. The cross-over design was implemented in eight trials but could be statistically considered in only four trials (<LINK REF="STD-Benes-1999" TYPE="STUDY">Benes 1999</LINK>; <LINK REF="STD-Brodeur-1988" TYPE="STUDY">Brodeur 1988</LINK>; <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>; <LINK REF="STD-Walker-1996" TYPE="STUDY">Walker 1996</LINK>). Duration of medication washout periods between the first and the second treatment were not reported or used in four of the cross-over trials. However, as treatment periods lasted for at least seven days, carryover effects for assessed post treatment effects were not likely. Two to six placebo controlled trials and one to three active controlled trials contributed data to meta-analyses. Those meta-analyses with only few studies have to be interpreted with caution. </P>
<P>Studies were reported with an often incomplete description of study procedures. In five studies, we could not obtain further information and thus had to rate their likelihood for bias conservatively as &#8221;unclear&#8221; even if we are aware that an insufficient study report does not necessarily represent inadequate performance of the study.</P>
<P>Marked heterogeneity was not observed in meta-analyses of placebo controlled studies. Heterogeneous results in active controlled trials were observed on the IRLS with more pronounced effects for cabergoline than pramipexole and regarding patients with adverse events with more patients experiencing adverse events in cabergoline and pergolide than in levodopa and slightly less experience of adverse events in pramipexole than in levodopa. These differences in treatment effects can be traced back to the different medications. A risk of the effective dopamine agonists cabergoline and pergolide is the known side effect valvular fibrosis, which requires medical monitoring and led in recent years to a preference of non-ergot dopamine agonists. Furthermore, impulse control disorders were observed recently during treatment with dopamine agonists (<LINK REF="REF-Cornelius-2010" TYPE="REFERENCE">Cornelius 2010</LINK>).</P>
<P>Results of the majority of meta-analyses in the placebo controlled trials showed precise small to large effects. In the placebo controlled trials, only the results on total sleep time and patients dropping out of treatment did not differ between levodopa and placebo and showed wide confidence intervals. In the active controlled trials five of eight evaluated endpoints revealed wide confidence intervals comprising a range from zero to a considerable effect.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-11-30 15:39:49 +0000" MODIFIED_BY="[Empty name]">
<P>We made an effort to prevent bias in the search for relevant trials and data as well as meta-analysis of included data. To identify all relevant studies, we searched all relevant databases without language restrictions. Data management was performed by two review authors. We asked pharmaceutical companies and study authors for additional information relevant to bias.</P>
<P>This work is independent of sponsoring of pharmaceutical companies, as it was supported by the German Ministry for Education and Research (Bundesministerium für Bildung und Forschung - BMBF, Project number DLR 01KG0723).</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-11-30 15:39:51 +0000" MODIFIED_BY="[Empty name]">
<P>One meta-analysis investigated levodopa treatment in RLS (<LINK REF="REF-Conti-2007" TYPE="REFERENCE">Conti 2007</LINK>). Results showed comparable effects on PLMSI and total sleep time to our meta-analysis. Other outcome parameters such as relief of symptoms, sleep quality, and quality of life were not analysed due to heterogeneity in outcome measurements between trials. We could analyse self rated data and by this, complete previous results.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-11-30 15:40:01 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2010-11-30 15:39:59 +0000" MODIFIED_BY="[Empty name]">
<P>Levodopa in doses from 100 mg to 200 mg proves to be an effective treatment option compared to placebo for short-term treatment (up to four weeks) of RLS. Evidence from the active controlled trials was in favour of dopamine agonists regarding three essential outcomes. The results of the other five endpoints do not favour any one treatment over another. However, due to imprecise results in these few trials, superiority of one agent cannot be ruled out. Tolerability proves to be satisfactory for patients treated with levodopa compared to cabergoline (<LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>; N = 361) and pergolide (<LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>; N = 11).</P>
<P>Data concerning long-term treatment efficacy is limited and the occurrence of augmentation, the most serious adverse event during dopaminergic treatment, is barely investigated.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-11-30 15:40:01 +0000" MODIFIED_BY="[Empty name]">
<P>Efficacy for short-term medication was proved in moderate to severely affected patients. However, for patients needing long-term medication, appropriate long-term studies including assessment of augmentation are necessary in order to be able to recommend levodopa for these patients. As no mechanism of action is known for levodopa in RLS, further research may concentrate on this aim to better understand dosages and long-term risks.</P>
<P>Besides comparison to placebo, levodopa needs to be tested against other dopaminergic and non-dopaminergic treatment options. Agents such as anticonvulsants and opioids present potent comparators. In all those studies, the occurrence and severity of augmentation should be evaluated.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-11-30 15:40:03 +0000" MODIFIED_BY="[Empty name]">
<P>This work was supported by a grant from the German Federal Ministry for Education and Research (Bundesministerium für Bildung und Forschung - BMBF, grant number DLR 01KG0723) to MH.</P>
<P>We also thank Carolin Laux for supporting the project during data collection and data management.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-05-20 15:33:46 +0100" MODIFIED_BY="[Empty name]">
<P>Hanna Scholz has no conflicts of interest to declare.</P>
<P>Claudia Trenkwalder has been an advisor for Boehringer Ingelheim, Cephalon, Mundipharm, Orion Pharma, Novartis, Solvay, Axxonis and UCB. She has received lecture honoraria from Boehringer Ingelheim, UCB, TEVA and Astra Zeneca.</P>
<P>Ralf Kohnen received honoraria for advisory board membership from Pfizer, USA; Axxonis, Germany; Roche, Germany; UCB, Germany; Jazzpharma, USA.</P>
<P>Dieter Riemann received research support from DFG, BMBF, EU (public funding) and from Takeda, Sanofi-Aventis, Organon, Actelion and Omron. He was on the speakers bureau of Sanofi-Aventis, Takeda, Servier, Lundbeck, Boehringer-Ingelheim, GSK, Cephalon and Merz Pharmaceuticals. He was also a member of advisory boards for Sanofi-Aventis, Lundbeck, GSK, Takeda and Actelion. Dr. Riemann declares that the above mentioned activities have no influence on the content of this article.</P>
<P>Levente Kriston has no conflicts of interest to declare.</P>
<P>Magdolna Hornyak received honoraria and/or lecture fees from Boehringer-Ingelheim, Germany; GlaxoSmithKline, Germany; Roche, Germany; Pfizer Inc., Germany.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-11-30 15:40:12 +0000" MODIFIED_BY="[Empty name]">
<P>MH: Performing previous work that was the foundation of the current review, conceiving the review, designing the review, co-ordinating the review, providing general advice on the review, securing funding for the review, screening of obtained publications regarding eligibility, appraising quality of papers, data collection for the review, writing to study authors for additional information, interpretation of data, writing the review, providing a clinical perspective, providing a policy perspective, providing a consumer perspective.</P>
<P>HS: Undertaking searches, screening search results, organizing retrieval of papers, screening retrieved publications regarding eligibility, appraising quality of papers, extracting data from papers, writing to study authors and pharmaceutical companies for additional information, obtaining and screening data on unpublished studies, data management for the review, entering data into RevMan, analysis of data, interpretation of data, writing the review, providing a methodological perspective.</P>
<P>CT: Performing previous work that was the foundation of the current review, co-ordinating the review, securing funding for the review, providing general advice on the review, interpretation of data, writing the review, providing a clinical perspective, providing a policy perspective, providing a consumer perspective.</P>
<P>RK: Performing previous work that was the foundation of the current review, conceiving the review, designing the review, co-ordinating the review, securing funding for the review, providing general advice on the review, providing additional data on included trials, interpretation of data, providing a methodological perspective.</P>
<P>LK: Conceiving the review, designing the review, providing general advice on the review, writing the protocol, designing search strategies, analysis of data, interpretation of data.</P>
<P>DR: Co-ordinating the review, securing funding for the review, providing general advice on the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2011-01-14 10:29:50 +0000" MODIFIED_BY="[Empty name]">
<P>Two outcomes defined in the protocol were specified in detail, two outcomes were added, and two outcome parameters were dropped after discussion in the light of actual research before the search for publications.</P>
<P>PLMS Index and number of patients dropping out due to adverse events were defined as primary and not as secondary outcome parameters. Total sleep time assessed in polysomnography was appended as a primary outcome.</P>
<P>We added clinician rated general improvement (CGI-I) and number of patients experiencing augmentation in the secondary outcome section. We excluded the planned outcomes &#8220;patient satisfaction with treatment&#8221; and &#8220;daytime functioning&#8221; as investigation of these endpoints in levodopa trials was very unlikely.</P>
<P>We investigated not only the first phase of cross-over trials, but included both phases of cross-over trials and corrected statistically for the different design when possible (see <LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 16.4).</P>
<P>We set search dates from 1985 (instead of 1990) to 2008 in order to obtain all possibly relevant trials. In order to be able to include all possibly relevant studies, trials did not have to implement explicit diagnostic criteria according to the IRLSSG (<LINK REF="REF-Walters-1995" TYPE="REFERENCE">Walters 1995</LINK>) but it was permitted to describe similar inclusion criteria of patients.</P>
<P>Search strategies were modified with respect to newly recommended strategies by the <LINK REF="REF-Reviewer_x0027_s-Handbook" TYPE="REFERENCE">Reviewer's Handbook</LINK>, chapter 6.</P>
<P>We conducted additional searches in online trial registers provided by pharmaceutical companies, the Pharmaceutical Research and Manufacturers of America (PhRMA) and the U.S. National Institutes for Health.</P>
<P>Instead of implementing fixed-effect models where data were homogeneous, we performed all meta-analyses using random-effects models as recommended by the Reviewer's Handbook. As only data for per protocol populations were reported, we performed analyses based on these data.</P>
<P>We could not perform any subgroup analyses on different types of agents, comparator treatment, duration of treatment or dosage of treatment as these parameters did not vary between the included studies. Also study type could not be investigated separately as all studies but one active controlled trial were cross-over trials. As only few studies contributed data to the primary outcomes, we did not perform subgroup or sensitivity analysis on studies with differing study quality.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-12-01 09:12:35 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-12-01 09:12:35 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Akpinar-1987" MODIFIED="2009-05-11 15:09:02 +0100" MODIFIED_BY="[Empty name]" NAME="Akpinar 1987" YEAR="1987">
<REFERENCE MODIFIED="2009-02-11 15:11:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Akpinar S</AU>
<TI>Restless legs syndrome treatment with dopaminergic drugs</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1987</YR>
<VL>10</VL>
<NO>1</NO>
<PG>69-79</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-11 15:07:38 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benes-1999" MODIFIED="2010-04-15 14:58:24 +0100" MODIFIED_BY="[Empty name]" NAME="Benes 1999" YEAR="">
<REFERENCE MODIFIED="2010-04-15 14:58:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Benes H, Kurella B, Kummer J, Kazenwadel J, Selzer R, Kohnen R</AU>
<TI>Rapid onset of action of levodopa in restless legs syndrome: a double-blind, randomized, multicenter, crossover trial</TI>
<SO>Sleep</SO>
<YR>1999</YR>
<VL>22</VL>
<NO>8</NO>
<PG>1073-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-BI-2006" MODIFIED="2010-12-01 09:12:35 +0000" MODIFIED_BY="[Empty name]" NAME="BI 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-12-01 09:12:35 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="OTHER">
<AU>248.518</AU>
<TI>A double-blind, randomised, crossover trial investigating the efficacy and safety of the dopamine agonist pramipexole (Sifrol®, 0.25-0.75 mg per day) versus levodopa / benserazide (Madopar® DR, 125-375 mg per day) in patients with restless legs syndrome</TI>
<SO>http://trials.boehringer-ingelheim.com/res/trial/data/pdf/248.518_U08-2249_upload.pdf</SO>
<YR>(accessed 16 March 2009)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-05-05 15:23:51 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mathis J, Bassetti C</AU>
<TI>Comparison of pramipexole (PPX) versus levodopa/benserazide (L/B) in the treatment of restless legs syndrome (RLS): A double blind, randomized, Swiss multi-centre crossover trial</TI>
<SO>Movement Disorders</SO>
<YR>2006</YR>
<VL>21 Suppl 15</VL>
<PG>S442</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brodeur-1988" MODIFIED="2010-04-15 15:00:04 +0100" MODIFIED_BY="[Empty name]" NAME="Brodeur 1988" YEAR="1988">
<REFERENCE MODIFIED="2010-04-15 14:59:56 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brodeur C, Montplaisir J, Godbout R, Marinier R</AU>
<TI>Treatment of restless legs syndrome and periodic movements during sleep with l-dopa: a double-blind, controlled study</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38</VL>
<PG>1845-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-04-15 15:00:04 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Montplaisir J, Boucher S, Gosselin A, Poirier G, Lavigne G</AU>
<TI>Persistence of repetitive EEG arousals (k-alpha complexes) in RLS patients treated with l-dopa</TI>
<SO>Sleep</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>196-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eisensehr-2004" MODIFIED="2010-04-15 15:00:12 +0100" MODIFIED_BY="[Empty name]" NAME="Eisensehr 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-04-15 15:00:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Eisensehr I, Ehrenberg B, Rogge Solti S, Noachtar S</AU>
<TI>Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/benserazid</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<PG>579-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staedt-1997" MODIFIED="2010-04-15 15:00:20 +0100" MODIFIED_BY="[Empty name]" NAME="Staedt 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-04-15 15:00:20 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staedt J, Waßmuth F, Ziemann U, Hajak G, Rüther E, Stoppe G</AU>
<TI>Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus l-dopa</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1997</YR>
<VL>104</VL>
<PG>461-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-1995" MODIFIED="2010-04-15 15:00:53 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-15 15:00:53 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Stiasny K, Pollmächster T, Wetter T, Schwarz J, Kohnen R, et al</AU>
<TI>L-dopa therapy of uremic and idiopathic restless legs syndrome: A double-blind, crossover trial</TI>
<SO>Sleep</SO>
<YR>1995</YR>
<VL>18</VL>
<NO>8</NO>
<PG>681-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2007" MODIFIED="2010-04-15 15:01:10 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-15 15:01:10 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Benes H, Grote L, Happe S, Högl B, Mathis J, et al</AU>
<TI>Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: results from a multicenter, randomized, active controlled trial</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>5</NO>
<PG>696-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Walker-1996" MODIFIED="2010-04-15 15:01:32 +0100" MODIFIED_BY="[Empty name]" NAME="Walker 1996" YEAR="1996">
<REFERENCE MODIFIED="2010-04-15 15:01:32 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Walker S, Fine A, Kryger M</AU>
<TI>L-DOPA/carbidopa for nocturnal movement disorders in uremia</TI>
<SO>Sleep</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>214-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-11-30 15:48:30 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Collado_x002d_Seidel-1997" MODIFIED="2010-11-30 15:43:15 +0000" MODIFIED_BY="[Empty name]" NAME="Collado-Seidel 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-11-30 15:43:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collado-Seidel V, Wetter T, Kohnen R, Kazenwald J, Selzer R, Oertel W, et al</AU>
<TI>Treatment of the restless legs syndrome with a combination of standard and sustained release levodopa/benserazide (Madopar Depot): A double-blind controlled study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>158</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Collado_x002d_Seidel-1999" MODIFIED="2010-04-15 15:02:01 +0100" MODIFIED_BY="[Empty name]" NAME="Collado-Seidel 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-04-15 15:02:01 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Collado-Seidel V, Kazenwadel J, Wetter T, Kohnen R, Winkelmann J, Selzer R, et al</AU>
<TI>A controlled study of additional sr-l-dopa in l-dopa-responsive restless legs syndrome with late night symptoms</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>52</VL>
<NO>2</NO>
<PG>285-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kaplan-1993" MODIFIED="2010-04-15 15:02:12 +0100" MODIFIED_BY="[Empty name]" NAME="Kaplan 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-04-15 15:02:12 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kaplan P, Allen R, Buchholz D, Walters J</AU>
<TI>A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene</TI>
<SO>Sleep 1993</SO>
<YR>16</YR>
<VL>8</VL>
<PG>717-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polo-2007" MODIFIED="2010-04-15 15:02:24 +0100" MODIFIED_BY="[Empty name]" NAME="Polo 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-04-15 15:02:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J</AU>
<TI>Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2007</YR>
<VL>30</VL>
<NO>6</NO>
<PG>335-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Polo-2008" MODIFIED="2010-11-30 15:43:33 +0000" MODIFIED_BY="[Empty name]" NAME="Polo 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-30 15:43:33 +0000" MODIFIED_BY="[Empty name]" NOTES="psyc" NOTES_MODIFIED="2010-11-30 15:43:33 +0000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Polo O, Ylä-Sahra R, Hirvonen K, Karvinen J, Vahteristo M, Ellmén J</AU>
<TI>'Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome': Erratum</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>2008</YR>
<VL>31</VL>
<NO>1</NO>
<PG>61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Reuter-1999" MODIFIED="2010-11-30 15:48:30 +0000" MODIFIED_BY="[Empty name]" NAME="Reuter 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-11-30 15:48:30 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Reuter I, Ellis C, Ray Chaudhuri K</AU>
<TI>Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome</TI>
<SO>Acta Neurologica Scandinavica</SO>
<YR>1999</YR>
<VL>100</VL>
<NO>3</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saletu-2003" MODIFIED="2010-11-30 15:43:23 +0000" MODIFIED_BY="[Empty name]" NAME="Saletu 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-11-30 15:43:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saletu M, Anderer P, Hogl B, Saletu-Zyhlarz G, Kunz A, Poewe W, et al</AU>
<TI>Acute double-blind, placebo-controlled sleep laboratory and clinical follow-up studies with a combination treatment of rr-L-dopa and sr-L-dopa in restless legs syndrome</TI>
<SO>Journal of Neural Transmission</SO>
<YR>2003</YR>
<VL>110</VL>
<NO>6</NO>
<PG>611-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Staedt-1998" MODIFIED="2009-05-05 15:57:40 +0100" MODIFIED_BY="[Empty name]" NAME="Staedt 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-05-05 15:57:40 +0100" MODIFIED_BY="[Empty name]" NOTES="med" NOTES_MODIFIED="2009-05-05 15:57:40 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Staedt J, Hunerjager H, Ruther E, Stoppe G</AU>
<TI>Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication</TI>
<SO>Journal of Neural Transmission</SO>
<YR>1998</YR>
<VL>105</VL>
<NO>2-3</NO>
<PG>265-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stiasny-2001" MODIFIED="2010-04-15 15:06:04 +0100" MODIFIED_BY="[Empty name]" NAME="Stiasny 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-04-15 15:06:04 +0100" MODIFIED_BY="[Empty name]" NOTES="med" NOTES_MODIFIED="2010-04-15 15:06:04 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny K</AU>
<TI>Clinical data on restless legs syndrome: a dose-finding study with cabergoline</TI>
<SO>European Neurology</SO>
<YR>2001</YR>
<VL>46 Suppl 1</VL>
<PG>24-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trenkwalder-2005" MODIFIED="2010-11-30 15:43:46 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-11-30 15:43:46 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Kohnen R</AU>
<TI>Augmentation and lack of efficacy with dopaminergic treatment in patients with RLS double blind comparison between cabergoline and l-dopa in the treatment of patients with severe restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2005</YR>
<VL>6 Suppl 2</VL>
<PG>S162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Scheele-1986" MODIFIED="2010-04-15 15:06:54 +0100" MODIFIED_BY="[Empty name]" NAME="von Scheele 1986" YEAR="1986">
<REFERENCE MODIFIED="2010-04-15 15:06:54 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Scheele C</AU>
<TI>Levodopa in restless legs</TI>
<SO>Lancet</SO>
<YR>1986</YR>
<VL>2</VL>
<NO>8504</NO>
<PG>426-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-von-Scheele-1990" MODIFIED="2010-11-30 15:43:54 +0000" MODIFIED_BY="[Empty name]" NAME="von Scheele 1990" YEAR="1990">
<REFERENCE MODIFIED="2010-11-30 15:43:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>von Scheele C, Kempi V</AU>
<TI>Long-term effect of dopaminergic drugs in restless legs. A 2-year follow-up</TI>
<SO>Archives of Neurology</SO>
<YR>1990</YR>
<VL>47</VL>
<NO>11</NO>
<PG>1223-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetter-1995" MODIFIED="2010-04-15 15:07:42 +0100" MODIFIED_BY="[Empty name]" NAME="Wetter 1995" YEAR="1995">
<REFERENCE MODIFIED="2010-04-15 15:07:42 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetter T, Trenkwalder C, Stiasny K, Pollmacher T, Kazenwadel J, Kohnen R, et al</AU>
<TI>[Treatment of idiopathic and uremic restless legs syndrome with L-dopa--a double-blind cross-over study]</TI>
<TO>Behandlung des idiopathischen und uramischen Restless-legs-Syndrom mit L-Dopa--Eine doppelblinde Cross-over-Studie</TO>
<SO>Wiener Medizinische Wochenzeitschrift</SO>
<YR>1995</YR>
<VL>145</VL>
<NO>17-18</NO>
<PG>525-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetter-1995a" MODIFIED="2010-04-15 15:09:19 +0100" MODIFIED_BY="[Empty name]" NAME="Wetter 1995a" YEAR="1995">
<REFERENCE MODIFIED="2010-04-15 15:09:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetter T, Trenkwalder C, Pollmacher T, Stiasny K, Kohnen R, Kazenwadel J, et al</AU>
<TI>Effect of levodopa therapy of idiopathic and uremic restless legs syndrome: a double blind crossover trial</TI>
<SO>Journal of Neurology</SO>
<YR>1995</YR>
<VL>242</VL>
<NO>6 Suppl 2</NO>
<PG>S81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-Yh-2008" MODIFIED="2010-11-30 15:44:13 +0000" MODIFIED_BY="[Empty name]" NAME="Wu Yh 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-11-30 15:44:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu Yh, Sun C, Wu D, Huang Y, Chi C</AU>
<TI>[Observation on therapeutic effect of acupuncture on restless legs syndrome]</TI>
<SO>Zhongguo zhen jiu [Chinese acupuncture &amp; moxibustion]</SO>
<YR>2008</YR>
<VL>28</VL>
<NO>1</NO>
<PG>27-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-04-14 10:38:33 +0100" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Akpinar-1982" MODIFIED="2010-04-21 08:41:58 +0100" MODIFIED_BY="[Empty name]" NAME="Akpinar 1982" TYPE="JOURNAL_ARTICLE">
<AU>Akpinar S</AU>
<TI>Treatment of restless legs syndrome with levodopa plus benserazide</TI>
<SO>Archives of Neurology</SO>
<YR>1982</YR>
<VL>39</VL>
<NO>11</NO>
<PG>739</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-1996" MODIFIED="2010-04-21 09:11:19 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 1996" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ</AU>
<TI>Augmentation of the restless legs syndrome with carbidopa/levodopa</TI>
<SO>Sleep</SO>
<YR>1996</YR>
<VL>19</VL>
<NO>3</NO>
<PG>205-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2003" MODIFIED="2010-04-15 15:09:41 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2003" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J</AU>
<TI>Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>101-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Allen-2007" MODIFIED="2010-06-02 12:17:36 +0100" MODIFIED_BY="[Empty name]" NAME="Allen 2007" TYPE="JOURNAL_ARTICLE">
<AU>Allen RP, Earley CJ</AU>
<TI>The role of iron in restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22 Suppl 18</VL>
<PG>S440-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-American-Academy-of-Sleep-Medicine-2005" MODIFIED="2010-06-02 12:15:27 +0100" MODIFIED_BY="[Empty name]" NAME="American Academy of Sleep Medicine 2005" TYPE="BOOK_SECTION">
<AU>American Academy of Sleep Medicine</AU>
<TI>Periodic limb movement disorder</TI>
<SO>The International classification of sleep disorders, 2nd edition: Diagnostic and coding manual</SO>
<YR>2005</YR>
<PG>182-6</PG>
<ED>American Academy of Sleep Medicine</ED>
<PB>American Academy of Sleep Medicine</PB>
<CY>Westchester, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Baker-2008" MODIFIED="2010-06-02 12:51:39 +0100" MODIFIED_BY="[Empty name]" NAME="Baker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Baker WL, White CM, Coleman CI</AU>
<TI>Effect of nonergot dopamine agonists on symptoms of restless legs syndrome</TI>
<SO>Annals of Family Medicine</SO>
<YR>2008</YR>
<VL>6</VL>
<NO>3</NO>
<PG>253-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2004" NAME="Berger 2004" TYPE="JOURNAL_ARTICLE">
<AU>Berger K, Luedemann J, Trenkwalder C, John U, Kessler C</AU>
<TI>Parity and the risk of restless legs syndrome in the general population</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2004</YR>
<VL>164</VL>
<NO>2</NO>
<PG>196-202</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Berger-2007" MODIFIED="2010-06-02 12:12:34 +0100" MODIFIED_BY="[Empty name]" NAME="Berger 2007" TYPE="JOURNAL_ARTICLE">
<AU>Berger K, Kurth T</AU>
<TI>RLS epidemiology - Frequencies, risk factors and methods in population studies</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<PG>S420-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonnet-1993" MODIFIED="2010-11-30 15:48:51 +0000" MODIFIED_BY="[Empty name]" NAME="Bonnet 1993" TYPE="JOURNAL_ARTICLE">
<AU>Bonnet M, Carley D, Carskadon M, Easton P, Guilleminault C, Harper R, et al</AU>
<TI>Recording And Scoring Leg Movements</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>748-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1988" MODIFIED="2010-06-02 12:57:48 +0100" MODIFIED_BY="[Empty name]" NAME="Cohen 1988" TYPE="BOOK">
<AU>Cohen J</AU>
<SO>Statistical Power Analysis in the Behavioral Sciences</SO>
<YR>1988</YR>
<EN>2nd edition</EN>
<PB>Lawrence Erlbaum Associates, Inc</PB>
<CY>Hillsdale (NJ)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-2008" MODIFIED="2010-06-02 12:18:32 +0100" MODIFIED_BY="[Empty name]" NAME="Connor 2008" TYPE="JOURNAL_ARTICLE">
<AU>Connor JR</AU>
<TI>Pathophysiology of restless legs syndrome: evidence for iron involvement</TI>
<SO>Current Neurology and Neuroscience Reports</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Connor-2009" MODIFIED="2010-11-30 15:44:26 +0000" MODIFIED_BY="[Empty name]" NAME="Connor 2009" TYPE="JOURNAL_ARTICLE">
<AU>Connor JR, Wang XS, Allen RP, Beard JL, Wiesinger JA, Felt BT, et al</AU>
<TI>Altered dopaminergic profile in the putamen and substantia nigra in  restless leg syndrome</TI>
<SO>Brain</SO>
<YR>2009</YR>
<VL>132</VL>
<NO>Pt 9</NO>
<PG>2403-12</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conti-2007" MODIFIED="2010-11-30 15:49:07 +0000" MODIFIED_BY="[Empty name]" NAME="Conti 2007" TYPE="JOURNAL_ARTICLE">
<AU>Conti CF, de Oliveira MM, Andriolo RB, Saconato H, Atallah AN, Valbuza JS, et al</AU>
<TI>Levodopa for idiopathic restless legs syndrome: evidence-based review</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>13</NO>
<PG>1943-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Conti-2008" MODIFIED="2010-04-15 15:10:41 +0100" MODIFIED_BY="[Empty name]" NAME="Conti 2008" TYPE="JOURNAL_ARTICLE">
<AU>Conti CF, Oliveira MM, Valbuza JS, Prado LB, Carvalho LB, Prado GF</AU>
<TI>Anticonvulsants to treat idiopathic restless legs syndrome: systematic review</TI>
<SO>Arquivos de Neuropsiquiatria</SO>
<YR>2008</YR>
<VL>66</VL>
<NO>2b</NO>
<PG>431-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornelius-2010" MODIFIED="2011-01-11 12:16:59 +0000" MODIFIED_BY="[Empty name]" NAME="Cornelius 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH</AU>
<TI>Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study</TI>
<SO>Sleep</SO>
<YR>2010</YR>
<VL>33</VL>
<NO>1</NO>
<PG>81-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Diagnostic-Classification-Steering-Committee-1990" MODIFIED="2009-04-27 15:20:44 +0100" MODIFIED_BY="[Empty name]" NAME="Diagnostic Classification Steering Committee 1990" TYPE="BOOK">
<AU>Diagnostic Classification Steering Committe, Thorpy MJ (chairman)</AU>
<SO>International classification of sleep disorders: diagnostic and coding manual</SO>
<YR>1990</YR>
<PB>American Sleep Disorders Association</PB>
<CY>Rochester, MN</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dworkin-2008" MODIFIED="2011-01-13 09:41:40 +0000" MODIFIED_BY="[Empty name]" NAME="Dworkin 2008" TYPE="JOURNAL_ARTICLE">
<AU>Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al</AU>
<TI>Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations</TI>
<SO>The Journal of Pain</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>2</NO>
<PG>105-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Eisensehr-2004" MODIFIED="2010-04-15 15:11:33 +0100" MODIFIED_BY="[Empty name]" NAME="Eisensehr 2004" TYPE="JOURNAL_ARTICLE">
<AU>Eisensehr I, Ehrenberg BL, Rogge Solti S, Noachtar S</AU>
<TI>Treatment of idiopathic restless legs syndrome (RLS) with slow-release valproic acid compared with slow-release levodopa/ benserazid</TI>
<SO>Journal of Neurology</SO>
<YR>2004</YR>
<VL>251</VL>
<PG>579-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ekbom-1945" NAME="Ekbom 1945" TYPE="JOURNAL_ARTICLE">
<AU>Ekbom K</AU>
<TI>Restless legs: a clinical study</TI>
<SO>Acta Medica Scandinavica</SO>
<YR>1945</YR>
<VL>158</VL>
<PG>1-123</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2002" MODIFIED="2010-05-25 09:14:44 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2002" TYPE="JOURNAL_ARTICLE">
<AU>García-Borreguero D, Larrosa O, de la Llave Y, Verger K, Masramon X, Hernandez G</AU>
<TI>Treatment of restless legs syndrome with gabapentin: a double-blind, cross-over study</TI>
<SO>Neurology</SO>
<YR>2002</YR>
<VL>59</VL>
<NO>10</NO>
<PG>1573-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2007a" MODIFIED="2010-11-30 15:49:20 +0000" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2007a" TYPE="JOURNAL_ARTICLE">
<AU>García-Borreguero D, Allen RP, Kohnen R, Högl B, Trenkwalder C, Oertel W, et al; International Restless Legs Syndrome Study Group</AU>
<TI>Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute</TI>
<SO>Sleep Medicine</SO>
<YR>2007</YR>
<VL>8</VL>
<NO>5</NO>
<PG>520-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garcia_x002d_Borreguero-2007b" MODIFIED="2010-05-12 10:54:31 +0100" MODIFIED_BY="[Empty name]" NAME="Garcia-Borreguero 2007b" TYPE="JOURNAL_ARTICLE">
<AU>García-Borreguero D, Allen RP, Benes H, Earley C, Happe S, Högl B, et al</AU>
<TI>Augmentation as a treatment complication of restless legs syndrome: concept and management</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22 Suppl 18</VL>
<PG>S476-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Goertelmeyer-1985" MODIFIED="2009-04-27 09:46:51 +0100" MODIFIED_BY="[Empty name]" NAME="Goertelmeyer 1985" TYPE="BOOK_SECTION">
<AU>Goertelmeyer R</AU>
<TI>On the development of a standardized sleep inventory for the assessment of sleep</TI>
<SO>Methods of sleep research</SO>
<YR>1985</YR>
<ED>Kubicki S, Herrmann W</ED>
<PB>Fischer</PB>
<CY>Stuttgart/New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hansen-2009" MODIFIED="2010-11-30 15:44:43 +0000" MODIFIED_BY="[Empty name]" NAME="Hansen 2009" TYPE="JOURNAL_ARTICLE">
<AU>Hansen RA, Song L, Moore CG, Gilsenan AW, Kim MM, Calloway MO, et al</AU>
<TI>Effect of ropinirole on sleep outcomes in patients with restless legs syndrome: meta-analysis of pooled individual patient data from randomized controlled trials</TI>
<SO>Pharmacotherapy</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>3</NO>
<PG>255-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Happe-2008" MODIFIED="2010-04-21 08:34:30 +0100" MODIFIED_BY="[Empty name]" NAME="Happe 2008" TYPE="JOURNAL_ARTICLE">
<AU>Happe S, Vennemann M, Evers S, Berger K</AU>
<TI>Treatment wish of individuals with known and unknown restless legs syndrome in the community</TI>
<SO>Journal of Neurology</SO>
<YR>2008</YR>
<VL>255</VL>
<NO>9</NO>
<PG>1365-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hening-2004" MODIFIED="2010-06-02 13:35:02 +0100" MODIFIED_BY="[Empty name]" NAME="Hening 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hening W</AU>
<TI>The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2004</YR>
<VL>115</VL>
<NO>9</NO>
<PG>1965-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hornyak-2004" MODIFIED="2010-05-21 13:16:49 +0100" MODIFIED_BY="[Empty name]" NAME="Hornyak 2004" TYPE="JOURNAL_ARTICLE">
<AU>Hornyak M, Trenkwalder C</AU>
<TI>Restless legs syndrome and periodic limb movement disorder in the elderly</TI>
<SO>Journal of Psychosomatic Research</SO>
<YR>2004</YR>
<VL>56</VL>
<PG>543-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-H_x00f6_gl-2003" MODIFIED="2010-04-15 15:17:51 +0100" MODIFIED_BY="[Empty name]" NAME="Högl 2003" TYPE="JOURNAL_ARTICLE">
<AU>Högl B, Saletu M, Frauscher B, Brandauer E, Seppi K, Müller J, et al</AU>
<TI>Prevalence of Restless Legs Syndrome in the central European alpine region of South Tyrol</TI>
<SO>Sleep</SO>
<YR>2003</YR>
<VL>26</VL>
<PG>A344</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Iber-2007" MODIFIED="2010-11-30 15:45:09 +0000" MODIFIED_BY="[Empty name]" NAME="Iber 2007" TYPE="BOOK">
<AU>Iber C, Ancoli-Israel S, Chesson A, Quan SF for the American Academy of Sleep Medicine</AU>
<SO>The AASM manual for the scoring of sleep and associated events: Rules, terminology and technical specifications</SO>
<YR>2007</YR>
<EN>first</EN>
<PB>American Academy of Sleep Medicine</PB>
<CY>Westchester, Illinois</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohnen-2002" MODIFIED="2009-04-27 09:45:36 +0100" MODIFIED_BY="[Empty name]" NAME="Kohnen 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kohnen R, Benes H, Heinrich CR, Kurella B</AU>
<TI>Development of the disease-specific Restless Legs Syndrome Quality of Life (RLS-QoL) questionnaire</TI>
<SO>Movement Disorders</SO>
<YR>2002</YR>
<VL>17 Suppl 5</VL>
<PG>P743</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kohnen-2004" MODIFIED="2010-03-04 09:56:34 +0000" MODIFIED_BY="[Empty name]" NAME="Kohnen 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kohnen R, Oertel WH, Stiasny-Kolster K, Benes H, Trenkwalder C</AU>
<TI>Severity rating of restless legs syndrome: validation of the RLS-6 scales</TI>
<SO>Sleep</SO>
<YR>2004</YR>
<VL>27 Suppl 1</VL>
<PG>A304. Abstract 680</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushida-2007" MODIFIED="2010-11-30 15:45:16 +0000" MODIFIED_BY="[Empty name]" NAME="Kushida 2007" TYPE="JOURNAL_ARTICLE">
<AU>Kushida C, Martin M, Nikam P, Blaisdell B, Wallenstein G, Ferini-Strambi L, et al</AU>
<TI>Burden of restless legs syndrome on health-related quality of life</TI>
<SO>Quality of Life Research</SO>
<YR>2007</YR>
<VL>16</VL>
<NO>4</NO>
<PG>617-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kushida-2009" MODIFIED="2010-06-02 13:48:24 +0100" MODIFIED_BY="[Empty name]" NAME="Kushida 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, Barrett RW; XP052 Study Group</AU>
<TI>Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS</TI>
<SO>Neurology</SO>
<YR>2009</YR>
<VL>72</VL>
<NO>5</NO>
<PG>439-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Manconi-2004" MODIFIED="2010-11-30 15:45:26 +0000" MODIFIED_BY="[Empty name]" NAME="Manconi 2004" TYPE="JOURNAL_ARTICLE">
<AU>Manconi M, Govoni V, De Vito A, Economou NT, Cesnik E, Mollica G, et al</AU>
<TI>Pregnancy as a risk factor for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2004</YR>
<VL>5</VL>
<NO>3</NO>
<PG>305-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-National-Institute-of-Mental-Health-1976" MODIFIED="2009-04-27 09:45:49 +0100" MODIFIED_BY="[Empty name]" NAME="National Institute of Mental Health 1976" TYPE="BOOK_SECTION">
<AU>National Institute of Mental Health (NIMH)</AU>
<TI>Early clinical drug evaluation unit (ECDEU). Clinical Global Impressions</TI>
<SO>ECDEU assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<EN>revised</EN>
<ED>Guy W</ED>
<PB>NIMH, Psychopharmacology Research Branch</PB>
<CY>Rockville MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Oertel-2007" MODIFIED="2010-11-30 15:49:49 +0000" MODIFIED_BY="[Empty name]" NAME="Oertel 2007" TYPE="JOURNAL_ARTICLE">
<AU>Oertel WH, Trenkwalder C, Zucconi M, Benes H, Borreguero DG, Bassetti C, et al</AU>
<TI>State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>2007</YR>
<VL>22 Suppl 18</VL>
<PG>S466-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Phillips-2000" MODIFIED="2010-04-15 15:18:25 +0100" MODIFIED_BY="[Empty name]" NAME="Phillips 2000" TYPE="JOURNAL_ARTICLE">
<AU>Phillips B, Young T, Finn L, Asher K, Hening WA, Purvis C</AU>
<TI>Epidemiology of restless legs symptoms in adults</TI>
<SO>Archives of Internal medicine</SO>
<YR>2000</YR>
<VL>160</VL>
<PG>2137-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Quilici-2008" MODIFIED="2010-11-30 15:45:34 +0000" MODIFIED_BY="[Empty name]" NAME="Quilici 2008" TYPE="JOURNAL_ARTICLE">
<AU>Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, et al</AU>
<TI>Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2008</YR>
<VL>9</VL>
<NO>7</NO>
<PG>715-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reviewer_x0027_s-Handbook" MODIFIED="2011-01-14 10:22:40 +0000" MODIFIED_BY="[Empty name]" NAME="Reviewer's Handbook" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions 5.0.1 [updated September 2008]. The Cochrane Collaboration, 2008</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rothdach-2000" MODIFIED="2010-04-15 15:18:37 +0100" MODIFIED_BY="[Empty name]" NAME="Rothdach 2000" TYPE="JOURNAL_ARTICLE">
<AU>Rothdach AJ, Trenkwalder C, Haberstock J, Keil U, Berger K</AU>
<TI>Prevalence and risk factors of RLS in an elderly population</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<PG>1064-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sch_x00f6_ls-1998" MODIFIED="2010-06-02 12:19:32 +0100" MODIFIED_BY="[Empty name]" NAME="Schöls 1998" TYPE="JOURNAL_ARTICLE">
<AU>Schöls L, Haan J, Riess O, Amoridis G, Przuntek H</AU>
<TI>Sleep disturbance in spinocerebellar ataxias: is the SCA3 mutation a cause of restless legs syndrome?</TI>
<SO>Neurology</SO>
<YR>1998</YR>
<VL>51</VL>
<PG>1603-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stefansson-2007" MODIFIED="2010-04-15 15:19:05 +0100" MODIFIED_BY="[Empty name]" NAME="Stefansson 2007" TYPE="JOURNAL_ARTICLE">
<AU>Stefansson H, Rye DB, Hicks A, Petursson H, Ingason A, Thorgeirsson TE</AU>
<TI>A genetic risk factor for periodic limb movements in sleep</TI>
<SO>New England Journal of Medicine</SO>
<YR>2007</YR>
<VL>357</VL>
<NO>7</NO>
<PG>639-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stiasny_x002d_Kolster-2006" MODIFIED="2009-06-25 10:22:23 +0100" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2006" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster K, Kohnen R, Möller JC, Trenkwalder C, Oertel WH</AU>
<TI>Validation of the "L-DOPA test" for diagnosis of restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>21</VL>
<NO>9</NO>
<PG>1333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stiasny_x002d_Kolster-2009" MODIFIED="2010-11-30 15:50:00 +0000" MODIFIED_BY="[Empty name]" NAME="Stiasny-Kolster 2009" TYPE="JOURNAL_ARTICLE">
<AU>Stiasny-Kolster</AU>
<TI>Restless legs syndrome</TI>
<TO>Restless-Legs-Syndrom</TO>
<SO>Somnology</SO>
<YR>2009</YR>
<VL>13</VL>
<NO>1</NO>
<PG>115-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Talati-2009" MODIFIED="2010-06-02 12:38:41 +0100" MODIFIED_BY="[Empty name]" NAME="Talati 2009" TYPE="JOURNAL_ARTICLE">
<AU>Talati R, Phung OJ, Mather J, Coleman CI</AU>
<TI>Effect of non-ergot dopamine agonists on health-related quality of life of patients with restless legs syndrome</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2009</YR>
<VL>43</VL>
<PG>813-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2004" MODIFIED="2010-04-15 15:19:21 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2004" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Paulus W</AU>
<TI>Why do restless legs occur at rest?-pathophysiology of neuronal structures in RLS. Neurophysiology of RLS (part 2)</TI>
<SO>Clinical Neurophysiology</SO>
<YR>2004</YR>
<VL>115</VL>
<NO>9</NO>
<PG>1975-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2005" MODIFIED="2010-06-02 10:09:30 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2005" TYPE="BOOK_SECTION">
<AU>Trenkwalder C, Benes H, Hornyak M, Riemann D, Stiasny K, Winkelmann J</AU>
<TI>Restless legs syndrome and periodic limb movement disorder</TI>
<TO>Restless Legs Syndrom und Periodic Limb Movement Disorder</TO>
<SO>Leitlinien für Diagnostik und Therapie in der Neurologie</SO>
<YR>2005</YR>
<ED>Diener CH</ED>
<PB>Thieme</PB>
<CY>Stuttgart</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2008" MODIFIED="2010-06-02 12:39:50 +0100" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2008" TYPE="JOURNAL_ARTICLE">
<AU>Trenkwalder C, Hening WA, Montagna P, Oertel WH, Allen RP, Walters AS, et al</AU>
<TI>Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice</TI>
<SO>Movement Disorders</SO>
<YR>2008</YR>
<VL>23</VL>
<NO>16</NO>
<PG>2267-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Trenkwalder-2010" MODIFIED="2010-11-30 15:50:16 +0000" MODIFIED_BY="[Empty name]" NAME="Trenkwalder 2010" TYPE="OTHER">
<AU>Trenkwalder C, Paulus W</AU>
<TI>Restless legs syndrome: pathophysiology, clinical presentation and management</TI>
<SO>Nature Reviews Neurology</SO>
<YR>in press</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulfberg-2001" MODIFIED="2010-04-15 15:19:31 +0100" MODIFIED_BY="[Empty name]" NAME="Ulfberg 2001" TYPE="JOURNAL_ARTICLE">
<AU>Ulfberg J, Nyström B, Carter N, Edling C</AU>
<TI>Prevalence of restless legs syndrome among men aged 18 to 64 years: An association with somatic disease and neuropsychiatric symptoms</TI>
<SO>Movement Disorders</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1159-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1993" MODIFIED="2010-11-30 15:45:41 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 1993" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, Wagner ML, Hening WA, Grasing K, Mills R, Chokroverty S, et al</AU>
<TI>Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo</TI>
<SO>Sleep</SO>
<YR>1993</YR>
<VL>16</VL>
<PG>327-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-1995" MODIFIED="2010-04-15 15:19:47 +0100" MODIFIED_BY="[Empty name]" NAME="Walters 1995" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, The International Restless Legs Syndrome Study Group</AU>
<TI>Toward a better definition of restless legs syndrome</TI>
<SO>Movement Disorders</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>634-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2003" MODIFIED="2010-12-01 10:03:07 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 2003" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al; International Restless Legs Syndrome Study Group</AU>
<TI>Validation of theInternational Restless Legs Syndrome Study Group rating scale for restless legs syndrome</TI>
<SO>Sleep Medicine</SO>
<YR>2003</YR>
<VL>4</VL>
<PG>121-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walters-2007" MODIFIED="2010-11-30 15:50:46 +0000" MODIFIED_BY="[Empty name]" NAME="Walters 2007" TYPE="JOURNAL_ARTICLE">
<AU>Walters AS</AU>
<TI>Restless legs syndrome and periodic limb movements in sleep</TI>
<SO>Continuum: Lifelong learning in Neurology</SO>
<YR>2007</YR>
<VL>13</VL>
<NO>3</NO>
<PG>115-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Winkelmann-2007" MODIFIED="2010-11-30 15:51:10 +0000" MODIFIED_BY="[Empty name]" NAME="Winkelmann 2007" TYPE="JOURNAL_ARTICLE">
<AU>Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al</AU>
<TI>Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions</TI>
<SO>Nature Genetics</SO>
<YR>2007</YR>
<VL>39</VL>
<NO>8</NO>
<PG>1000-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zintzaras-2010" MODIFIED="2010-11-30 15:46:03 +0000" MODIFIED_BY="[Empty name]" NAME="Zintzaras 2010" TYPE="JOURNAL_ARTICLE">
<AU>Zintzaras E, Kitsios GD, Papathanasiou AA, Konitsiotis S, Miligkos M, Rodopoulou P, et al</AU>
<TI>Randomized trials of dopamine agonists in restless legs syndrome: a systematic review, quality assessment, and meta-analysis</TI>
<SO>Clinical Therapeutics</SO>
<YR>2010</YR>
<VL>32</VL>
<NO>2</NO>
<PG>221-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zucconi-2006" MODIFIED="2010-11-30 15:51:21 +0000" MODIFIED_BY="[Empty name]" NAME="Zucconi 2006" TYPE="JOURNAL_ARTICLE">
<AU>Zucconi M, Ferri R, Allen R, Baier PC, Bruni O, Chokroverty S, et al; International Restless Legs Syndrome Study Group (IRLSSG)</AU>
<TI>The official World Association of Sleep Medicine (WASM) standards for recording and scoring periodic leg movements in sleep (PLMS) and wakefulness (PLMW) developed in collaboration with a task force from the International Restless Legs Syndrome Study Group (IRLSSG)</TI>
<SO>Sleep Medicine</SO>
<YR>2006</YR>
<VL>7</VL>
<NO>2</NO>
<PG>175-83</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2011-01-14 11:37:02 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2011-01-14 11:37:02 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="funding source" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2010-11-21 14:54:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Akpinar-1987">
<CHAR_METHODS MODIFIED="2010-05-21 12:50:25 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa versus placebo</P>
<P>Dropouts/withdrawals: Total N of 16, alternative medication for 3 patients</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-21 13:03:37 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed:16/13</P>
<P>Demographics: 6 male, age 49.6 years</P>
<P>Diagnosis: patients with moderate to severe RLS</P>
<P>Setting: 1 centre in Turkey</P>
<P>Baseline: 6 patients rated as having severe, 10 patients rated as having moderate symptoms</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 12:46:09 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed single dose of 200 mg/50 mg levodopa/benserazide for 14 days</P>
<P>Control: fixed single dose of placebo capsules for 14 days</P>
<P>No washout between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-30 09:38:11 +0100" MODIFIED_BY="[Empty name]">
<P>Safety: Number of dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-21 14:54:25 +0000" MODIFIED_BY="[Empty name]">
<P>No funding stated.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-02 14:08:04 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Benes-1999">
<CHAR_METHODS MODIFIED="2010-05-21 12:50:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa versus placebo</P>
<P>Dropouts/withdrawals: PP of 32 with premature discontinuations of 3 patients in the treatment group.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-21 12:52:07 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 35/32</P>
<P>Demographics: 13 male, age 56 years</P>
<P>Diagnosis: RLS according to IRLSSG, PLMS/h &gt; 5, symptoms for at least 2 weeks, sleep onset latency &gt; 30 min and/or sleep efficiency &#8804; 85%</P>
<P>Setting: 3 centres in Germany</P>
<P>Baseline: PLMI (using actigraphy) 49.5 ± 29.2</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 12:48:18 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible uptitration of single dose levodopa/benserazide from 100 mg/25 mg to 200 mg/50 mg in 3 weeks, maintenance for 1 week</P>
<P>Control: flexible uptitration of single dose placebo capsules in 3 weeks, maintenance for 1 week</P>
<P>No washout between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-02 14:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Change of symptoms: CGI-Improvement</P>
<P>Objective quality of sleep: PLM-Index (using actigraphy)</P>
<P>Self rated quality of sleep: SF-A</P>
<P>Quality of life: VAS on life satisfaction</P>
<P>Safety: Number of drop outs due to adverse events, number of patients experiencing adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-06-02 14:04:52 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by a grant from Hoffmann La-Roche, Inc.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-21 12:48:58 +0100" MODIFIED_BY="[Empty name]">
<P>PLMI: index of number of periodic limb movements per hour time in bed; CGI-I: Clinical Gobla Impressions - Improvement; SF-A: Schlaffragebogen-A; VAS: Visual Analogue Scale</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-12-01 10:00:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-BI-2006">
<CHAR_METHODS MODIFIED="2010-05-21 12:51:44 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa dual release versus pramipexole</P>
<P>Dropouts/withdrawals: PP of 39 with 28 premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 13:58:31 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 67/39</P>
<P>Demographics: 41% male, age 56.9 years</P>
<P>Diagnosis: RLS according to IRLSSG, symptom presence almost every day, PLMI &gt; 5</P>
<P>Setting: 6 Swiss centres including Basel, Bern, Lugano, Luzern, Zürich, Zurzach</P>
<P>Baseline: IRLS score of 21.1 (levodopa) and 20.8 (ppx), PLMI (actigraphy) of 21.1 (levodopa) and 21.5 (ppx)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-12-01 10:00:09 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention 1: flexible uptitration of single dose pramipexole from 0.25 to 0.75 mg in 2 weeks, maintenance for 2 weeks</P>
<P>Intervention 2: flexible uptitration of single dose levodopa-dual-release from 100/25 mg to 300/75 mg for 2 weeks, maintenance for 2 weeks</P>
<P>2 weeks washout between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-21 12:52:58 +0100" MODIFIED_BY="[Empty name]">
<P>Change of symptoms: IRLS, CGI responders</P>
<P>Objective quality of sleep: PLMI (using actigraphy)</P>
<P>Safety: number of dropouts due to adverse events, number of patients with adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:51:58 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Boehringer Ingelheim GmbH. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-21 12:52:37 +0100" MODIFIED_BY="[Empty name]">
<P>IRLS: International RLS Severity Rating Scale; ppx: pramipexole</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:40:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brodeur-1988">
<CHAR_METHODS MODIFIED="2010-06-02 13:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa versus placebo</P>
<P>Dropouts/withdrawals: Total N of 6, no premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 13:58:44 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 6/6</P>
<P>Demographics: 3 male, age 51.3 years</P>
<P>Diagnosis: primary RLS according to clinical evaluation, nocturnal awakenings and daytime sleepiness</P>
<P>Setting: 1 centre in Canada</P>
<P>Baseline: PLMSI (using PSG) 38.2 ± 12.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-11-30 15:40:50 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed dose of 100 mg/25 mg levodopa/benserazide twice daily (1hour before, 3 hours after going to bed) for 14 days</P>
<P>Control: fixed dose of placebo capsules twice daily (1hour before, 3 hours after going to bed) for 14 days</P>
<P>Washout for 1 week between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-21 12:55:20 +0100" MODIFIED_BY="[Empty name]">
<P>Objective quality of sleep: change in sleep parameters (TST), PLMSI (using PSG)</P>
<P>Safety: Number of dropouts due to adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:46:46 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by the Medical Research Council of Canada, the Fonds de la recherche en santé du Québec and the Fond pour la formation de chercheurs et l'aide à la recherche du Québec. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-21 12:58:29 +0100" MODIFIED_BY="[Empty name]">
<P>TST: total sleep time; PSG: polysomnography</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-11-30 15:40:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eisensehr-2004">
<CHAR_METHODS MODIFIED="2010-06-02 13:58:50 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of slow-release levodopa versus slow-release valproic acid versus placebo</P>
<P>Dropouts/withdrawals: Total N of 20, no premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 13:58:56 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 20/20</P>
<P>Demographics: 8 male, age 58.9 years</P>
<P>Diagnosis: primary RLS according to IRLSSG, PLM/h &gt; 10, symptoms daily for at least 6 months</P>
<P>Setting: 1 centre in Germany</P>
<P>Baseline: PLMSI (using PSG) 42.3 ± 40.7</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 12:56:25 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention 1: fixed single dose of 200 mg/50 mg slow-release-levodopa/benserazide (after 2 days of 100 mg/25 mg) for 3 weeks</P>
<P>Intervention 2: fixed single dose of slow-release-valproic acid (600 mg after 2 days of 300 mg) for 3 weeks</P>
<P>Control: fixed single dose of placebo capsules for 3 weeks</P>
<P>No washout between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-21 12:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Change of symptoms: Rating of severity of symptoms in the past 24 hours</P>
<P>Objective quality of sleep: TST, PLMSI (using PSG)</P>
<P>Safety: Number of dropouts due to adverse events, number of patients experiencing adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-11-30 15:40:53 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by Sanofi pharmaceutical company.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-02 13:59:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staedt-1997">
<CHAR_METHODS MODIFIED="2010-06-02 13:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised active controlled crossover trial of levodopa versus pergolide</P>
<P>Dropouts/withdrawals: Total N of 11, no premature discontinuations</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 13:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 11</P>
<P>Demographics: 6 male, age 57.6 years</P>
<P>Diagnosis: patients with a history of restlessness and paraesthesias at night and/or day</P>
<P>Setting: 1 centre in Germany</P>
<P>Baseline: PLMS-disturbed time of sleep 164 ± 80.4 min</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 12:59:15 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention 1: flexible uptitration of single dose levodopa/benserazide from 200 mg/50 mg to 400 mg/100 mg in 16 days</P>
<P>Intervention 2: flexible uptitration of single dose pergolide from 0.125 mg to 0.25 mg in 16 days</P>
<P>Washout of 24 hours between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-03-30 11:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Objective quality of sleep: Change in sleep parameters (TST)</P>
<P>Safety: Number of dropouts due to adverse events, number of patients experiencing adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-03-30 11:05:42 +0100" MODIFIED_BY="[Empty name]">
<P>No funding stated.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-06-02 14:05:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-1995">
<CHAR_METHODS MODIFIED="2010-05-21 12:59:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa versus placebo</P>
<P>Dropouts/withdrawals: PP of 28, 4 premature discontinuations (2 before drug intake)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 14:05:26 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 32/28</P>
<P>Demographics: 18 male, age 52.0 years</P>
<P>Diagnosis: primary and secondary RLS according to descriptive criteria, PLMS-AI &gt; 5, sleep onset latency &gt; 25 and/or sleep efficiency &lt; 85%</P>
<P>Setting: 1 centre in Germany</P>
<P>Baseline: severity on RLS rating scale 7.9 (0 to 10 points = severe)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 13:00:07 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: flexible uptitration of single dose levodopa/benserazide from 100 mg/25 mg to 200 mg/50 mg in 2 weeks, maintenance for 2 weeks</P>
<P>Control: single dose placebo capsules for 4 weeks</P>
<P>No washout between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-02 14:05:30 +0100" MODIFIED_BY="[Empty name]">
<P>Change of symptoms: CGI-I, VAS on severity of RLS symptoms during the night</P>
<P>Objective quality of sleep: TST, PLMSI (using PSG)</P>
<P>Self rated quality of sleep: VAS on quality of sleep</P>
<P>Quality of Life: VAS on life satisfaction</P>
<P>Safety: Number of dropouts due to adverse events, number of patients experiencing adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:55:15 +0100" MODIFIED_BY="[Empty name]">
<P>No funding stated. </P>
</CHAR_USER_DEF_1>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-01-14 11:37:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2007">
<CHAR_METHODS MODIFIED="2009-06-09 15:28:30 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised active controlled parallel-group trial of levodopa versus cabergoline</P>
<P>Dropouts/withdrawals: ITT (361) and PP (204) with premature discontinuations of 83 (levodopa) and 74 (cabergoline)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-06-02 13:59:34 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: long term: 361 patients (178 cabergoline, 183 levodopa), short term: 204 (104 cabergoline, 100 levodopa)</P>
<P>Demographics: 46 (levodopa)/58 (cabergoline) male, age 56.9 (levodopa)/58.7 (cabergoline)</P>
<P>Diagnosis: RLS according to IRLSSG, symptom severity on IRLS &#8805; 10 and RLS-6 "severity at night" &#8805; 4.</P>
<P>Setting: 51 centres in 4 European countries</P>
<P>Baseline: IRLS score of 25.6 (levodopa) and 25.8 (cabergoline)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-01-14 11:37:02 +0000" MODIFIED_BY="[Empty name]">
<P>Intervention 1: fixed uptitration of single dose cabergoline to 2.0 mg which could be increased to 3.0 mg (in 2 weeks), maintenance up to 6/ 8 weeks and to 24 weeks</P>
<P>Intervention 2: fixed uptitration of single dose levodopa/benserazide 200 mg/50 mg (in 8 days) which could be increased to to 300 mg/75 mg, maintenance up to 6/ 8 weeks and to 24 weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-06-02 14:05:37 +0100" MODIFIED_BY="[Empty name]">
<P>Change of symptoms: IRLS, CGI-I</P>
<P>Self rated quality of sleep: RLS-6 satisfaction with sleep</P>
<P>Daytime tiredness: RLS-6 daytime tiredness</P>
<P>Quality of life: RLS-QoL</P>
<P>Safety: number of dropouts due to adverse events, number of patients with adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-05-11 14:57:05 +0100" MODIFIED_BY="[Empty name]">
<P>The study was supported by Pfizer GmbH.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2010-05-21 13:02:28 +0100" MODIFIED_BY="[Empty name]">
<P>RLS-QoL: Restless Legs Syndrome Quality of Life questionnaire</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-05-21 13:03:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Walker-1996">
<CHAR_METHODS MODIFIED="2009-06-09 15:29:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomised controlled crossover trial of levodopa versus placebo</P>
<P>Dropouts/withdrawals: PP (5) with premature discontinuations of 3 patients prior to start of trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-05-21 13:02:55 +0100" MODIFIED_BY="[Empty name]">
<P>Included/analysed: 8/5</P>
<P>Demographics: 1 male, age 68.2 years</P>
<P>Diagnosis: RLS according to <LINK REF="REF-Diagnostic-Classification-Steering-Committee-1990" TYPE="REFERENCE">Diagnostic Classification Steering Committee 1990</LINK>
</P>
<P>Setting: 1 centre in Canada</P>
<P>No baseline values given</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-05-21 13:03:08 +0100" MODIFIED_BY="[Empty name]">
<P>Intervention: fixed single dose of 100 mg/25 mg levodopa/carbidopa for 1 week</P>
<P>Control: fixed single dose of placebo capsules for 1 week</P>
<P>Washout for 1 week between treatment periods</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-05-21 13:03:17 +0100" MODIFIED_BY="[Empty name]">
<P>Objective quality of sleep: Change in sleep parameters (TST), PLMSI (using PSG)</P>
<P>Safety: number of dropouts due to adverse events, number of patients with adverse events</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-11-10 11:23:00 +0000" MODIFIED_BY="[Empty name]">
<P>The study was supported by the Kidney Foundation of Canada, Manitoba Branch, The Medical Research Council of Canada and Baxter Healthcare corporation.</P>
</CHAR_USER_DEF_1>
<CHAR_NOTES MODIFIED="2009-04-14 10:38:23 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-12-01 10:02:00 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collado_x002d_Seidel-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:26 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the congress abstract were published in Collado-Seidel (1999).</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Collado_x002d_Seidel-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:28 +0000" MODIFIED_BY="[Empty name]">
<P>Double-blind comparison of sr-ldopa additionally to rr-ldopa versus placebo additional to rr-ldopa.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:34 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kaplan-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:34 +0000" MODIFIED_BY="[Empty name]">
<P>Diagnosis of PLMS/h &gt; 5 in all patients, RLS-symptoms were present only in 3 patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:38 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:38 +0000" MODIFIED_BY="[Empty name]">
<P>Medication period was only two nights.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Polo-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:39 +0000" MODIFIED_BY="[Empty name]">
<P>Erratum of excluded study <LINK REF="STD-Polo-2007" TYPE="STUDY">Polo 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Reuter-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:41 +0000" MODIFIED_BY="[Empty name]">
<P>Results of two patients with RLS only analysed descriptively.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:43 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Saletu-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:43 +0000" MODIFIED_BY="[Empty name]">
<P>Medication period was only one night.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Staedt-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:45 +0000" MODIFIED_BY="[Empty name]">
<P>Open label follow-up of <LINK REF="STD-Staedt-1997" TYPE="STUDY">Staedt 1997</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stiasny-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:48 +0000" MODIFIED_BY="[Empty name]">
<P>Preliminary data which were published later in <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Trenkwalder-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:50 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the congress abstract were published in <LINK REF="STD-Trenkwalder-2007" TYPE="STUDY">Trenkwalder 2007</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:51 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Scheele-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:51 +0000" MODIFIED_BY="[Empty name]">
<P>Treatment of levodopa and placebo on alternate days.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-von-Scheele-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:53 +0000" MODIFIED_BY="[Empty name]">
<P>Two year open label follow-up.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wetter-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:56 +0000" MODIFIED_BY="[Empty name]">
<P>German duplicate of study of <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:01:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wetter-1995a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:01:58 +0000" MODIFIED_BY="[Empty name]">
<P>Results of the congress abstract were published in <LINK REF="STD-Trenkwalder-1995" TYPE="STUDY">Trenkwalder 1995</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-12-01 10:02:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-Yh-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-12-01 10:02:00 +0000" MODIFIED_BY="[Empty name]">
<P>Observational study on levodopa versus acupuncture.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-04-14 10:38:33 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2008-11-21 13:39:16 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-12-01 09:59:52 +0000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-06-02 12:08:33 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:00:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>Patients were treated randomly.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-21 12:53:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Randomisation schedule was provided by BI Pharma GmbH &amp; Co KG.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:02:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>Randomisation list was produced by the statistical department of the sponsor.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:41 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>Randomisation was done by the sponsor with a computer based system.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-06-02 12:08:33 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Sequentially assigned to one of the two treatments by the investigators using medication numbers in ascending order for each block of 4 which was allocated to the study site after central randomisation using the program SAS Proc. Plan Version v8.2.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:18:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-11-30 15:40:41 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:00:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>Double-blind crossover basis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Medication package with the lowest available number was allocated to the patient.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-11-30 15:40:41 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>Patients had to be allocated to a numbered medication in ascending order. Due to the blinding of the medication, investigators and patients were not informed regarding treatment sequence or medication.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>Capsules were distributed when requested by blinded executor mentioning patient number and treatment session.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-05-21 13:00:32 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>Patient randomisation numbers were allocated sequentially in the order of recruitment of patients. The allocated number was then the patient code.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:17:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Medication numbers in ascending order. See above.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:18:04 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>Insufficient information.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-12-01 09:59:52 +0000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-12-01 09:59:52 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>Insufficient information</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-05-20 15:30:55 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Tablets were packaged in identical hard gelatine capsules, the code was restricted to authorised personnel, such as staff involved in packaging of study medication. Blinding of data analysts not reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 15:40:43 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>White capsules of identical size and shape, the capsules were not differentiable. The capsules which had to be taken in one cross-over period were filled in a glass and labelled with "week 3-6" and "week 7-10", respectively. Blinding of polysomnography raters was not mentioned.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 09:11:06 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>No information concerning blinding of staff, examiners, polysomnography analysis.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 09:11:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>Similar looking and tasting capsules, physicians did not know about sequences until end of study when analysis was completed.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-11-30 15:40:59 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Insufficient information, not mentioned if research staff were blinded.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 09:15:46 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>Unblinding was done after the complete database had been transferred to the sponsor.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 09:18:18 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Identical looking tablets.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-03-30 09:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>Blinded scorers for PSG rating.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-03-30 09:18:19 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:00:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:10:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Dropouts and reasons reported by BI on request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:08:38 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:10:51 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>All patients were included in analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:11:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:11:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:16:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:18:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Dropouts and reasons described.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2010-03-30 09:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>No incomplete outcome data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-03-30 09:33:04 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:00:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>All results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Results reported as prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:08:34 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>All results reported as prespecified with additional sleep data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>No outcomes prespecified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:26 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>All results reported as prespecified with additional sleep data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:45 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>All results reported as prespecified, additional sleep data reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:16:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>All results reported as prespecified with additional questionnaire data.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:17:11 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>All results reported as prespecified with further report of short term data for secondary outcomes following request.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:33:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>All results reported as prespecified with results of additional sleep parameters partly reported.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-03-30 09:18:20 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:00:24 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Akpinar-1987">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-BI-2006">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:08:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Benes-1999">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:10:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brodeur-1988">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Eisensehr-2004">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:11:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Staedt-1997">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:16:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-1995">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:18:20 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Trenkwalder-2007">
<DESCRIPTION>
<P>Low indication of other bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-03-30 09:18:07 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Walker-1996">
<DESCRIPTION>
<P>Low indication of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-11-30 15:42:09 +0000" MODIFIED_BY="[Empty name]">
<SOF_TABLE ID="SOF-01" MODIFIED="2010-11-30 15:42:02 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-30 15:41:20 +0000" MODIFIED_BY="[Empty name]">Summary of findings: levodopa versus placebo</TITLE>
<TABLE COLS="7" ROWS="14">
<TR>
<TD COLSPAN="7">
<P>
<B>Levodopa compared with placebo for restless legs syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients with restless legs syndrome</P>
<P>
<B>Intervention: </B>levodopa for at least seven days</P>
<P>
<B>Comparison: </B>levodopa for at least seven days</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Placebo</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Levodopa</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>1</B>
</P>
<P>
<B>Severity of symptoms </B>(rating from 0 = not present to 10 = severe)</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean symptom severity rating ranged across control groups from<BR/>5.2 to 5.5</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean symptom severity rating in the intervention groups was<BR/>-1.34 lower (95 CI -2.18 to -0.50)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>48</P>
<P>(2 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Estimated effect based on only two studies.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>2</B>
</P>
<P>
<B>Periodic limb movements in sleep index (PLMSI)</B>
</P>
<P>PLMS per hour of sleep (4 trials) or time in bed (1 trial)</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PLMSI ranged across control groups from<BR/>36.9 to 101</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PLMSI in the intervention groups was<BR/>-26.28 lower (95 CI -30.53 to -22.02)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>91</P>
<P>(5 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Blinding of polysomnography raters was not reported in most studies.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>3</B>
</P>
<P>
<B>Total sleep time</B>
</P>
<P>
<B>(TST)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean TST ranged across control groups from<BR/>260 to 397.4</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean TST in the intervention groups was<BR/>5.86 higher (95% CI -18.56 to 30.28)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>59</P>
<P>(4 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P>The confidence interval shows no to a considerable effect. Blinding of polysomnography raters was not reported in most studies.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>4</B>
</P>
<P>
<B>Dropouts due to adverse events</B>
</P>
</TD>
<TD>
<P>0 of 1000</P>
</TD>
<TD>
<P>0 of 1000</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.73 (95% CI 0.05 to 11.34)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>109</P>
<P>(6 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>The confidence interval shows no to a considerable effect.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>5</B>
</P>
<P>
<B>Clinical Global Impressions - Improvement of condition (CGI-I)</B>
</P>
<P>Rating of 1 = very much improved to 7 = very much worse</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean CGI-I ranged across control groups from<BR/>4.4 to 4.8</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean CGI-I in the intervention groups was<BR/>-1.25 lower (95% CI -1.89 to -0.62)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>60<BR/>(2 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Estimated effect based on only two studies.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>6</B>
</P>
<P>
<B>Self rated quality of sleep</B>
</P>
<P>SMD on SF-A scale quality of sleep and VAS (0 to 10 = very good night)</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>The mean SMD in the intervention groups was<BR/>0.92 higher (95 % CI 0.52 to 1.33)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>60</P>
<P>(2 studies)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Estimated effect based on only two studies.</P>
<P>No data for placebo group can be given due to the standardized analysis.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>7</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>VAS on life satisfaction (0 to 50 = high)</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean life satisfaction ranged across control groups from 21.6 to 23.8<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean life satisfaction in the intervention groups was<BR/>3.23 higher (95% CI 1.64 to 4.82)</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>60</P>
<P>(2 studies)<BR/>
</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Estimated effect based on only two studies.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; RR: Risk Ratio; OR: Odds Ratio; VAS: Visual Analogue Scale</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2010-11-30 15:42:09 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-30 15:41:28 +0000" MODIFIED_BY="[Empty name]">Summary of findings: levodopa versus other dopamine agonists</TITLE>
<TABLE COLS="7" ROWS="13">
<TR>
<TD COLSPAN="7">
<P>
<B>Dopamine agonists compared with levodopa for restless legs syndrome</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population: </B>patients with restless legs syndrome</P>
<P>
<B>Settings: </B>outpatient settings in Europe</P>
<P>
<B>Intervention: </B>treatment with dopamine agonists cabergoline, pergolide, pramipexole for at least seven days</P>
<P>
<B>Comparison: </B>treatment with levodopa for at least seven days<B> </B>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Outcomes</P>
</TH>
<TH ALIGN="CENTER" COLSPAN="2" VALIGN="MIDDLE">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>No of Participants<BR/>(studies)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="CENTER" ROWSPAN="3" VALIGN="MIDDLE">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Assumed risk</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Dopamine agonists</P>
</TH>
<TH ALIGN="CENTER" VALIGN="MIDDLE">
<P>Levodopa</P>
</TH>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>1</B>
</P>
<P>
<B>IRLS</B>
</P>
<P>range: 0 to 40</P>
<P>(= severe)</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean IRLS change ranged across dopamine agonist groups from<BR/>-7.2 to -16.06.</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean IRLS change in the levodopa groups was<BR/>5.25 smaller (95% CI 2.1 to 8.4).</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>383<BR/>(2 studies)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD>
<P>Estimated effect based on only two studies.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>2</B>
</P>
<P>
<B>Periodic limb movements per hour of time in bed (PLMI)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean PLMI was -11.5 in the pramipexole group.</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean change on the PLMI in the levodopa group was<BR/>3.80 smaller (95% CI -1.48 to 9.08, P = 0.16).</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>39<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD>
<P>Methods of the study were not well reported. Estimated effect based on only one study.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>3</B>
</P>
<P>
<B>Total sleep time (TST)</B>
</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean TST was 421 in the pergolide group.</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean TST in the levodopa group was -76.00 smaller (95% CI -155.82 to 3.82, P = 0.06).</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>11</P>
<P>(1 study)</P>
</TD>
<TD ALIGN="CENTER">
<P>+OOO</P>
<P>very low</P>
</TD>
<TD>
<P>Methods of one included study were not well reported, very low doses of pergolide were implemented, the confidence interval of the effect shows no to a considerable effect.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>4</B>
</P>
<P>
<B>Number of drop outs due to adverse events</B>
</P>
</TD>
<TD>
<P>0 per 100</P>
</TD>
<TD>
<P>0 per 100</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>OR 0.59 (95% CI 0.33 to 1.04, P = 0.07)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>504</P>
<P>(3 studies)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>The confidence interval of the effect shows no to a considerable effect.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>5</B>
</P>
<P>
<B>Clinical Global Impressions - Improvement of condition (CGI-I)</B>
</P>
<P>Rating of 1 = very much improved to 7 = very much worse</P>
</TD>
<TD>
<P>The mean CGI-I was 1.76 in cabergoline.</P>
</TD>
<TD>
<P>The mean change in CGI-I in the levodopa group was 0.62 (95% CI 0.37 to 0.87), i.e. further apart from a rating of "1 = very much improved".</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P/>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>344<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT" VALIGN="MIDDLE">
<P>Estimated effect based on only one study.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>6</B>
</P>
<P>
<B>Self rated quality of sleep</B>
</P>
<P>RLS-6; scale satisfaction with sleep: 0 to 10 (= low satisfaction)</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean change in satisfaction with sleep was -3.43 in cabergoline.</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean change in satisfaction with sleep in the levodopa group was<BR/>0.63 smaller (05% CI -0.09 to 1.35, P = 0.09).</P>
</TD>
<TD ALIGN="CENTER">
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>344<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER">
<P>++OO<BR/>low</P>
</TD>
<TD ALIGN="LEFT">
<P>The confidence interval of the effect shows no to a considerable effect. Estimated effect based on only one study.</P>
<P>The treatment difference was not significant.</P>
</TD>
</TR>
<TR>
<TD ALIGN="CENTER">
<P>
<B>7</B>
</P>
<P>
<B>Quality of life</B>
</P>
<P>RLS-QoL: 0 to 60 (= severe impairment)</P>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>The mean change in quality of life was -15.92 in cabergoline.</P>
</TD>
<TD ALIGN="CENTER">
<P>The mean change in RLS-QoL in the levodopa group was<BR/>5.54 smaller (95% CI 2.65 to 8.43).</P>
</TD>
<TD>
<P/>
</TD>
<TD ALIGN="CENTER">
<P>
<BR/>314<BR/>(1 study)</P>
</TD>
<TD ALIGN="CENTER">
<P>+++O<BR/>moderate</P>
</TD>
<TD ALIGN="LEFT">
<P>Estimated effect based on only one study.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% CI) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<BR/>CI: Confidence interval; OR: Odds Ratio; RR: Risk Ratio; IRLS: International RLS Severity Rating Scale; RLS-QoL: Restless Legs Syndrome Quality of Life questionnaire</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality (++++):</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality (+++O):</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality (++OO):</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality (+OOO):</B> We are very uncertain about the estimate.</P>
</FOOTNOTES>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2011-01-14 10:14:54 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2011-01-14 10:14:54 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-04-08 08:59:06 +0100" MODIFIED_BY="[Empty name]">Diagnosis criteria of Restless legs syndrome</TITLE>
<TABLE COLS="1" ROWS="4">
<TR>
<TD>
<P>
<B>Essential criteria</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>1. An urge to move the legs, usually accompanied or caused by uncomfortable and unpleasant sensations in the legs (sometimes the urge to move is present without the uncomfortable sensations and sometimes the arms or other body parts are involved in addition to the legs).</P>
<P>2. The urge to move or unpleasant sensations begin or worsen during periods of rest or inactivity such as lying or sitting.</P>
<P>3. The urge to move or unpleasant sensations are partially or totally relieved by movement, such as walking or stretching, at least as long as the activity continues.</P>
<P>4. The urge to move or unpleasant sensations are worse in the evening or night than during the day or only occur in the evening or night (when symptoms are very severe, the worsening at night may not be noticeable but must have been present previously).</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Supportive criteria and associated features of RLS</B>
</P>
</TD>
</TR>
<TR>
<TD>
<UL>
<LI>Positive family history</LI>
<LI>Response to dopaminergic therapy</LI>
<LI>Periodic limb movements (during wakefulness or sleep)</LI>
<LI>Natural clinical course</LI>
<LI>Sleep disturbance</LI>
</UL>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2010-05-20 15:25:50 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-05-20 15:25:50 +0100" MODIFIED_BY="[Empty name]">Additional trials/ information retrieved from the Internet</TITLE>
<TABLE COLS="3" ROWS="3">
<TR>
<TD>
<P>
<B>Online resource</B>
</P>
</TD>
<TD ALIGN="CENTER" VALIGN="MIDDLE">
<P>
<B>Retrieved trials</B>
</P>
</TD>
<TD VALIGN="MIDDLE">
<P>
<B>Additional information for published trials</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical study results</P>
</TD>
<TD>
<P>0</P>
</TD>
<TD>
<P>1</P>
</TD>
</TR>
<TR>
<TD>
<P>Boehringer-Ingelheim</P>
</TD>
<TD>
<P>1</P>
</TD>
<TD>
<P>0</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>
<U>Internet sites:</U>
</P>
<P>www.clinicalstudyresults.org</P>
<P>http://trials.boehringer-ingelheim.com</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2010-06-02 14:08:08 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-04-07 16:13:06 +0100" MODIFIED_BY="[Empty name]">Summary of questionnaires in trials and their scoring</TITLE>
<TABLE COLS="3" ROWS="6">
<TR>
<TD>
<P>
<B>Questionnaire</B>
</P>
</TD>
<TD>
<P>
<B>Description</B>
</P>
</TD>
<TD>
<P>
<B>Measurement</B>
</P>
</TD>
</TR>
<TR>
<TD>
<P>IRLS</P>
<P>(<LINK REF="REF-Walters-2003" TYPE="REFERENCE">Walters 2003</LINK>)</P>
</TD>
<TD>
<P>Symptom severity scale with a total score of 0 to 40 for 10 questions (rating 0 to 4).</P>
</TD>
<TD>
<P>Mild RLS: 0 to 10</P>
<P>Moderate RLS: 11 to 20</P>
<P>Severe RLS: 21 to 30</P>
<P>Very severe RLS: 31 to 40</P>
</TD>
</TR>
<TR>
<TD>
<P>Clinical Global Impressions - Improvement (<LINK REF="REF-National-Institute-of-Mental-Health-1976" TYPE="REFERENCE">National Institute of Mental Health 1976</LINK>)</P>
</TD>
<TD>
<P>Evaluation by clinician regarding improvement of condition.</P>
</TD>
<TD>
<P>Rating 1 (very much better) to 7 (very much worse)</P>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>SF-A</P>
<P>(<LINK REF="REF-Goertelmeyer-1985" TYPE="REFERENCE">Goertelmeyer 1985</LINK>)</P>
</TD>
<TD>
<P>Subscore of questions regarding self rated quality of sleep.</P>
</TD>
<TD>
<P>Rating 1 to 5</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>RLS-6 satisfaction with sleep</P>
<P>(<LINK REF="REF-Kohnen-2004" TYPE="REFERENCE">Kohnen 2004</LINK>)</P>
</TD>
<TD>
<P>Question regarding satisfaction with sleep in the past 7 days.</P>
</TD>
<TD>
<P>Rating 0 (totally satisfied) to 10 (totally unsatisfied)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
<TR>
<TD>
<P>QoL-RLS</P>
<P>(<LINK REF="REF-Kohnen-2002" TYPE="REFERENCE">Kohnen 2002</LINK>)</P>
</TD>
<TD>
<P>Total score of 12 questions investigating health related quality of life in RLS patients (6-point Likert scale).</P>
</TD>
<TD>
<P>0 to 60 (high impairment)</P>
<P>&#8594; transformed into SMD</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES>
<P>IRLS: International RLS Severity Rating Scale; SF-A: Schlaffragebogen-A; QoL-RLS: Restless Legs Syndrome Quality of Life questionnaire</P>
</FOOTNOTES>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2011-01-14 10:08:21 +0000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2011-01-13 10:04:51 +0000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Levodopa versus placebo</NAME>
<IV_OUTCOME CHI2="0.2091776702836971" CI_END="-0.5036678525364786" CI_START="-2.1799509211594295" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-1.341809386847954" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-21 13:23:40 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6474127152658861" P_Q="1.0" P_Z="0.0017023652514613445" Q="0.0" RANDOM="YES" SCALE="4.21" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="3.137773233610475">
<NAME>Change on severity scales</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="0.23277550948723702" CI_START="-2.432775509487237" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-24 11:04:20 +0000" MODIFIED_BY="[Empty name]" ORDER="3" SE="0.68" STUDY_ID="STD-Eisensehr-2004" TOTAL_1="20" TOTAL_2="20" WEIGHT="39.5476532880115"/>
<IV_DATA CI_END="-0.42201980850297005" CI_START="-2.57798019149703" EFFECT_SIZE="-1.5" ESTIMABLE="YES" ESTIMATE="-1.5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-24 11:01:12 +0000" MODIFIED_BY="[Empty name]" ORDER="858" SE="0.55" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="60.45234671198849"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="4.179412484091484" CI_END="-22.023958892271352" CI_START="-30.53198884582988" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_SIZE="-26.277973869050616" ESTIMABLE="YES" I2="4.292768057098935" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-21 13:23:56 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.3822692435752062" P_Q="1.0" P_Z="9.683130680031607E-34" Q="0.0" RANDOM="YES" SCALE="77.11" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="1.1846191372844839" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="12.107122953529823">
<NAME>Periodic limb movements in sleep</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-19.6677328970472" CI_START="-34.132267102952795" EFFECT_SIZE="-26.9" ESTIMABLE="YES" ESTIMATE="-26.9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-29 11:50:16 +0100" MODIFIED_BY="[Empty name]" ORDER="25" SE="3.69" STUDY_ID="STD-Benes-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="31.828709443237706"/>
<IV_DATA CI_END="-20.739707686225238" CI_START="-32.460292313774765" EFFECT_SIZE="-26.6" ESTIMABLE="YES" ESTIMATE="-26.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-29 11:50:15 +0100" MODIFIED_BY="[Empty name]" ORDER="27" SE="2.99" STUDY_ID="STD-Brodeur-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="46.52847971227224"/>
<IV_DATA CI_END="-4.190351150734472" CI_START="-42.40964884926553" EFFECT_SIZE="-23.3" ESTIMABLE="YES" ESTIMATE="-23.3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-29 11:50:15 +0100" MODIFIED_BY="[Empty name]" ORDER="461" SE="9.75" STUDY_ID="STD-Eisensehr-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="4.894565086147127"/>
<IV_DATA CI_END="-5.175830138789053" CI_START="-30.224169861210946" EFFECT_SIZE="-17.7" ESTIMABLE="YES" ESTIMATE="-17.7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-29 11:50:14 +0100" MODIFIED_BY="[Empty name]" ORDER="26" SE="6.39" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="11.211912749121938"/>
<IV_DATA CI_END="-22.0467299016131" CI_START="-57.953270098386895" EFFECT_SIZE="-40.0" ESTIMABLE="YES" ESTIMATE="-40.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-29 11:50:14 +0100" MODIFIED_BY="[Empty name]" ORDER="24" SE="9.16" STUDY_ID="STD-Walker-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="5.536333009220988"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="2.1576092098855018" CI_END="30.276089238514153" CI_START="-18.56420936396595" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_SIZE="5.855939937274103" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.4810997766463578" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="0.7675966136370503" MODIFIED="2010-05-21 13:24:12 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.5403462940225634" P_Q="1.0" P_Z="0.6383561542466643" Q="0.0" RANDOM="YES" SCALE="98.2" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="0.4699984111933404">
<NAME>Total sleep time</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="79.75571665496483" CI_START="-38.155716654964834" EFFECT_SIZE="20.8" ESTIMABLE="YES" ESTIMATE="20.8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-15 09:10:28 +0000" MODIFIED_BY="[Empty name]" ORDER="28" SE="30.08" STUDY_ID="STD-Brodeur-1988" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.15713560358219"/>
<IV_DATA CI_END="26.186850518278526" CI_START="-55.38685051827853" EFFECT_SIZE="-14.6" ESTIMABLE="YES" ESTIMATE="-14.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-15 09:10:27 +0000" MODIFIED_BY="[Empty name]" ORDER="39" SE="20.81" STUDY_ID="STD-Eisensehr-2004" TOTAL_1="0" TOTAL_2="0" WEIGHT="35.847286528902444"/>
<IV_DATA CI_END="93.81851917604703" CI_START="-23.818519176047033" EFFECT_SIZE="35.0" ESTIMABLE="YES" ESTIMATE="35.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-15 09:10:27 +0000" MODIFIED_BY="[Empty name]" ORDER="29" SE="30.01" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="17.23726890524332"/>
<IV_DATA CI_END="49.76557740689484" CI_START="-39.76557740689484" EFFECT_SIZE="5.0" ESTIMABLE="YES" ESTIMATE="5.0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-15 09:10:26 +0000" MODIFIED_BY="[Empty name]" ORDER="860" SE="22.84" STUDY_ID="STD-Walker-1996" TOTAL_1="0" TOTAL_2="0" WEIGHT="29.75830896227205"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="1.5137037745040214" CI_END="11.343737997884636" CI_START="0.04678345991141732" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7284911199662336" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" I2="33.936876101953374" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="1.054756187216021" LOG_CI_START="-1.3299076627134574" LOG_EFFECT_SIZE="-0.13757573774871817" METHOD="MH" MODIFIED="2010-05-21 13:24:23 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.21857519195306052" P_Q="0.0" P_Z="0.8210863058788305" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.3334135973429933" TOTALS="YES" TOTAL_1="109" TOTAL_2="109" WEIGHT="100.0" Z="0.22614800919801709">
<NAME>Number of drop outs due to adverse events</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="38" O_E="0.0" SE="0.0" STUDY_ID="STD-Akpinar-1987" TOTAL_1="13" TOTAL_2="13" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="4.077241641947999" CI_START="0.008736278055420703" EFFECT_SIZE="0.18873239436619718" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6103664511271016" LOG_CI_START="-2.058673551835637" LOG_EFFECT_SIZE="-0.7241535503542676" ORDER="33" O_E="0.0" SE="1.5678073097014071" STUDY_ID="STD-Benes-1999" TOTAL_1="35" TOTAL_2="35" VAR="2.4580197603531637" WEIGHT="51.75187789994841"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-09 14:50:11 +0000" MODIFIED_BY="[Empty name]" ORDER="39" O_E="0.0" SE="0.0" STUDY_ID="STD-Brodeur-1988" TOTAL_1="6" TOTAL_2="6" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-09 14:50:36 +0000" MODIFIED_BY="[Empty name]" ORDER="35" O_E="0.0" SE="0.0" STUDY_ID="STD-Eisensehr-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="79.22786759281833" CI_START="0.12142837665097087" EFFECT_SIZE="3.1016949152542375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8988779671075169" LOG_CI_START="-0.9156798109309462" LOG_EFFECT_SIZE="0.4915990780882853" MODIFIED="2010-02-24 12:35:31 +0000" MODIFIED_BY="[Empty name]" ORDER="32" O_E="0.0" SE="1.6532851711054914" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="30" TOTAL_2="30" VAR="2.7333518569973143" WEIGHT="48.24812210005159"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-11-09 14:51:57 +0000" MODIFIED_BY="[Empty name]" ORDER="36" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker-1996" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<IV_OUTCOME CHI2="0.22707939508506592" CI_END="-0.617484240799148" CI_START="-1.892515759200852" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="-1.255" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_DATA="NO" LOG_EFFECT_SIZE="NaN" MODIFIED="2010-05-21 13:24:47 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="0.6336979403716083" P_Q="1.0" P_Z="1.1415811904251112E-4" Q="0.0" RANDOM="YES" SCALE="5.67" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.8583435234309436">
<NAME>CGI-Improvement</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="-0.5084165671115749" CI_START="-2.311583432888425" EFFECT_SIZE="-1.41" ESTIMABLE="YES" ESTIMATE="-1.41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-12 10:45:44 +0000" MODIFIED_BY="[Empty name]" ORDER="463" SE="0.46" STUDY_ID="STD-Benes-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0"/>
<IV_DATA CI_END="-0.19841656711157507" CI_START="-2.001583432888425" EFFECT_SIZE="-1.1" ESTIMABLE="YES" ESTIMATE="-1.1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-12 10:45:45 +0000" MODIFIED_BY="[Empty name]" ORDER="41" SE="0.46" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="50.0"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.002281802624073022" CI_END="1.3261384504041156" CI_START="0.517227208466392" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="0.9216828294352538" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.12258886728722027" LOG_CI_START="-0.2863186373569769" LOG_DATA="NO" LOG_EFFECT_SIZE="-0.03541850315887737" MODIFIED="2010-05-21 13:25:04 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.9619009794333887" P_Q="1.0" P_Z="7.954262356535431E-6" Q="0.0" RANDOM="YES" SCALE="1.5" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="4.466411287682777">
<NAME>Change in self rated quality of sleep</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<EFFECT_MEASURE>Std. Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="1.4591902758258146" CI_START="0.40080972417418537" EFFECT_SIZE="0.93" ESTIMABLE="YES" ESTIMATE="0.93" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-09 13:01:31 +0000" MODIFIED_BY="[Empty name]" ORDER="465" SE="0.27" STUDY_ID="STD-Benes-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="58.41414717626925"/>
<IV_DATA CI_END="1.5371884750528175" CI_START="0.28281152494718265" EFFECT_SIZE="0.91" ESTIMABLE="YES" ESTIMATE="0.91" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-09 12:05:53 +0000" MODIFIED_BY="[Empty name]" ORDER="464" SE="0.32" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="41.58585282373075"/>
</IV_OUTCOME>
<IV_OUTCOME CHI2="0.7422498883983926" CI_END="4.815199262446774" CI_START="1.635387017995665" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_SIZE="3.2252931402212197" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.6826142637950271" LOG_CI_START="0.21362054591992424" LOG_DATA="NO" LOG_EFFECT_SIZE="0.5085691928921828" MODIFIED="2011-01-13 10:04:51 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.38894114086542064" P_Q="1.0" P_Z="7.008567150065294E-5" Q="0.0" RANDOM="YES" SCALE="11.45" SHOW_PARTICIPANTS="NO" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="0" TOTAL_2="0" WEIGHT="100.0" Z="3.9759947496578554">
<NAME>Change in quality of life</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<EFFECT_MEASURE>Mean Difference</EFFECT_MEASURE>
<IV_DATA CI_END="4.653567225931449" CI_START="1.0864327740685507" EFFECT_SIZE="2.87" ESTIMABLE="YES" ESTIMATE="2.87" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-09 13:06:27 +0000" MODIFIED_BY="[Empty name]" ORDER="466" SE="0.91" STUDY_ID="STD-Benes-1999" TOTAL_1="0" TOTAL_2="0" WEIGHT="79.46282426466941"/>
<IV_DATA CI_END="8.108335532326697" CI_START="1.0916644676733025" EFFECT_SIZE="4.6" ESTIMABLE="YES" ESTIMATE="4.6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-02-24 12:33:46 +0000" MODIFIED_BY="[Empty name]" ORDER="467" SE="1.79" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="0" TOTAL_2="0" WEIGHT="20.537175735330592"/>
</IV_OUTCOME>
<DICH_OUTCOME CHI2="0.11775877353718121" CI_END="5.036776067676655" CI_START="1.3540432584509385" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="2.6115153989139337" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="37" I2="0.0" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="0.7021526427905651" LOG_CI_START="0.13163253924309645" LOG_EFFECT_SIZE="0.4168925910168308" METHOD="MH" MODIFIED="2010-05-21 13:25:34 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.942820484538999" P_Q="0.0" P_Z="0.004178205298669202" Q="0.0" RANDOM="YES" SCALE="26.52" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="88" TOTAL_2="88" WEIGHT="99.99999999999999" Z="2.8643844756176615">
<NAME>Number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.70219003681421" CI_START="1.0342224154983881" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="20" LOG_CI_END="0.9396285631027111" LOG_CI_START="0.014613946336613734" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2010-02-24 12:44:05 +0000" MODIFIED_BY="[Empty name]" ORDER="42" O_E="0.0" SE="0.5433581647846061" STUDY_ID="STD-Benes-1999" TOTAL_1="35" TOTAL_2="35" VAR="0.2952380952380952" WEIGHT="38.0403683819376"/>
<DICH_DATA CI_END="8.106217238488194" CI_START="0.6355836808582133" EFFECT_SIZE="2.2698412698412698" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="9" LOG_CI_END="0.908818238217972" LOG_CI_START="-0.19682726219501195" LOG_EFFECT_SIZE="0.35599548801148007" ORDER="45" O_E="0.0" SE="0.6494616399760819" STUDY_ID="STD-Eisensehr-2004" TOTAL_1="20" TOTAL_2="20" VAR="0.42180042180042177" WEIGHT="26.626255742704636"/>
<DICH_DATA CI_END="7.548095753583032" CI_START="0.8280234120020493" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="8" LOG_CI_END="0.8778374008978966" LOG_CI_START="-0.0819573835538212" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2010-02-24 12:48:57 +0000" MODIFIED_BY="[Empty name]" ORDER="43" O_E="0.0" SE="0.5637882074477462" STUDY_ID="STD-Trenkwalder-1995" TOTAL_1="28" TOTAL_2="28" VAR="0.31785714285714284" WEIGHT="35.33337587535776"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="44" O_E="0.0" SE="0.0" STUDY_ID="STD-Walker-1996" TOTAL_1="5" TOTAL_2="5" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-01-14 10:08:21 +0000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Levodopa versus other dopamine agonists</NAME>
<CONT_OUTCOME CHI2="2.233597109977393" CI_END="8.39943234904382" CI_START="2.098387419982116" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="5.248909884512968" ESTIMABLE="YES" I2="55.22916843270265" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2010-05-21 13:26:08 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.1350392369614305" P_Q="1.0" P_Z="0.0010931470596973925" Q="0.0" RANDOM="YES" SCALE="10.85" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="3.0254814613276624" TOTALS="YES" TOTAL_1="216" TOTAL_2="206" UNITS="" WEIGHT="100.0" Z="3.265386756502199">
<NAME>Change on IRLS</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Dopamine agonist</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<CONT_DATA CI_END="6.998696528236108" CI_START="-0.5986965282361081" EFFECT_SIZE="3.2" ESTIMABLE="YES" MEAN_1="-4.0" MEAN_2="-7.2" MODIFIED="2010-03-30 12:43:45 +0100" MODIFIED_BY="[Empty name]" ORDER="589" SD_1="7.5" SD_2="9.5" SE="1.938146087479026" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" WEIGHT="38.0993992594269"/>
<CONT_DATA CI_END="8.61066341398292" CI_START="4.409336586017076" EFFECT_SIZE="6.509999999999998" ESTIMABLE="YES" MEAN_1="-9.55" MEAN_2="-16.06" MODIFIED="2010-03-30 12:43:45 +0100" MODIFIED_BY="[Empty name]" ORDER="590" SD_1="9.68" SD_2="10.17" SE="1.0717867422833716" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="177" TOTAL_2="167" WEIGHT="61.900600740573104"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.7133965377495467E-32" CI_END="9.083986250962228" CI_START="-1.48398625096223" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.7999999999999994" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-05-21 13:26:19 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.0" P_Q="1.0" P_Z="0.1586826470528002" Q="0.0" RANDOM="YES" SCALE="25.9" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="39" UNITS="" WEIGHT="100.0" Z="1.409515995598196">
<NAME>Periodic limb movements per time in bed</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Pramipexole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours pramipexole</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.08398625096223" CI_START="-1.4839862509622295" EFFECT_SIZE="3.8" ESTIMABLE="YES" MEAN_1="-7.7" MEAN_2="-11.5" MODIFIED="2010-03-30 12:46:40 +0100" MODIFIED_BY="[Empty name]" ORDER="46" SD_1="9.5" SD_2="13.9" SE="2.6959608914457807" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="3.8200104352648196" CI_START="-155.8200104352648" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-76.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-05-21 13:26:29 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.062018366477831564" Q="0.0" RANDOM="YES" SCALE="188.25" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="11" TOTAL_2="11" UNITS="" WEIGHT="100.0" Z="1.8661644118156389">
<NAME>Total sleep time</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Pergolide</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours pergolide</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours levodopa</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.8200104352648196" CI_START="-155.8200104352648" EFFECT_SIZE="-76.0" ESTIMABLE="YES" MEAN_1="345.0" MEAN_2="421.0" MODIFIED="2010-04-07 13:26:26 +0100" MODIFIED_BY="[Empty name]" ORDER="41" SD_1="120.0" SD_2="62.0" SE="40.72524345593841" STUDY_ID="STD-Staedt-1997" TOTAL_1="11" TOTAL_2="11" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9379474053902609" CI_END="1.03814206901159" CI_START="0.33219064080832333" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.587248737039969" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="35" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.016256790473714647" LOG_CI_START="-0.47861260759371127" LOG_EFFECT_SIZE="-0.23117790855999829" METHOD="MH" MODIFIED="2011-01-14 10:08:21 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.3328064372469005" P_Q="0.0" P_Z="0.06707193053511988" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="257" TOTAL_2="247" WEIGHT="100.0" Z="1.8311917308621124">
<NAME>Number of dropouts due to adverse events</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Dopamine agonists</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_DATA CI_END="70.3075516897093" CI_START="0.11214818053682966" EFFECT_SIZE="2.808" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8470019748211117" LOG_CI_START="-0.9502077679055764" LOG_EFFECT_SIZE="0.4483971034577676" MODIFIED="2011-01-14 10:08:21 +0000" MODIFIED_BY="[Empty name]" ORDER="587" O_E="0.0" SE="1.6430948492891952" STUDY_ID="STD-BI-2006" TOTAL_1="63" TOTAL_2="58" VAR="2.6997606837606836" WEIGHT="3.1299048327592485"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-03-30 11:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="586" O_E="0.0" SE="0.0" STUDY_ID="STD-Staedt-1997" TOTAL_1="11" TOTAL_2="11" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.9960131398373219" CI_START="0.31294248577795253" EFFECT_SIZE="0.5582963620230701" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="35" LOG_CI_END="-0.0017349321373453153" LOG_CI_START="-0.5045354720523693" LOG_EFFECT_SIZE="-0.25313520209485735" MODIFIED="2010-03-30 11:48:51 +0100" MODIFIED_BY="[Empty name]" ORDER="588" O_E="0.0" SE="0.29534752604889825" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="183" TOTAL_2="178" VAR="0.08723016114320462" WEIGHT="96.87009516724075"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.8650475102651087" CI_START="0.37495248973489104" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6199999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.05" MODIFIED="2010-05-21 13:27:02 +0100" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="7.087621721852157E-7" Q="0.0" RANDOM="YES" SCALE="1.99" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="4.958947222520942">
<NAME>CGI-Improvement</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Cabergoline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cabergoline</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8650475102651087" CI_START="0.37495248973489104" EFFECT_SIZE="0.6199999999999999" ESTIMABLE="YES" MEAN_1="2.38" MEAN_2="1.76" MODIFIED="2010-04-07 13:31:38 +0100" MODIFIED_BY="[Empty name]" ORDER="42" SD_1="1.29" SD_2="1.02" SE="0.12502653732314079" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="177" TOTAL_2="167" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.3492731627965484" CI_START="-0.08927316279654762" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.6300000000000003" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" MODIFIED="2010-05-21 13:27:12 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.0860337277858108" Q="0.0" RANDOM="YES" SCALE="4.47" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="177" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="1.7167014899588313">
<NAME>Change in self rated quality of sleep</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Cabergoline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cabergoline</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.3492731627965484" CI_START="-0.08927316279654762" EFFECT_SIZE="0.6300000000000003" ESTIMABLE="YES" MEAN_1="-2.8" MEAN_2="-3.43" MODIFIED="2010-04-13 15:03:18 +0100" MODIFIED_BY="[Empty name]" ORDER="43" SD_1="3.35" SD_2="3.45" SE="0.3669828468635561" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="177" TOTAL_2="167" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.619099835585503E-31" CI_END="8.433663498541671" CI_START="2.6463365014583258" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="5.539999999999998" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-002.07" MODIFIED="2010-05-21 13:27:19 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.0" P_Q="1.0" P_Z="1.7514546442648764E-4" Q="0.0" RANDOM="YES" SCALE="10.36" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="164" TOTAL_2="150" UNITS="" WEIGHT="100.0" Z="3.7524060692696763">
<NAME>Change in disease specific quality of life</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Cabergoline</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours cabergoline</GRAPH_LABEL_2>
<CONT_DATA CI_END="8.433663498541671" CI_START="2.6463365014583267" EFFECT_SIZE="5.539999999999999" ESTIMABLE="YES" MEAN_1="-10.38" MEAN_2="-15.92" MODIFIED="2010-05-06 15:22:12 +0100" MODIFIED_BY="[Empty name]" ORDER="44" SD_1="12.08" SD_2="13.91" SE="1.476386056767635" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="164" TOTAL_2="150" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="5.430975152407606" CI_END="2.3033211435750935" CI_START="0.05262156008835776" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3481441539928851" ESTIMABLE="YES" EVENTS_1="141" EVENTS_2="174" I2="63.17420087784088" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="0.36235449426434163" LOG_CI_START="-1.2788362803909208" LOG_EFFECT_SIZE="-0.4582408930632896" METHOD="MH" MODIFIED="2011-01-11 11:43:55 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.06617287664401705" P_Q="0.0" P_Z="0.2737389720956114" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.7631979799434148" TOTALS="YES" TOTAL_1="233" TOTAL_2="228" WEIGHT="100.0" Z="1.0944926824075945">
<NAME>Number of patients experiencing adverse events</NAME>
<GROUP_LABEL_1>Levodopa</GROUP_LABEL_1>
<GROUP_LABEL_2>Dopamine agonists</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours levodopa</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours DAs</GRAPH_LABEL_2>
<DICH_DATA CI_END="77.90545984597716" CI_START="0.12160385596195605" EFFECT_SIZE="3.0779220779220777" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="38" LOG_CI_END="1.8915678953861497" LOG_CI_START="-0.9150526537109057" LOG_EFFECT_SIZE="0.488257620837622" MODIFIED="2011-01-11 11:43:54 +0000" MODIFIED_BY="[Empty name]" ORDER="583" O_E="0.0" SE="1.6486228035353918" STUDY_ID="STD-BI-2006" TOTAL_1="39" TOTAL_2="39" VAR="2.717957148336895" WEIGHT="20.739742483493696"/>
<DICH_DATA CI_END="0.4331253276245822" CI_START="0.0032467507908447418" EFFECT_SIZE="0.0375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="-0.3633864195350401" LOG_CI_START="-2.488551045009522" LOG_EFFECT_SIZE="-1.4259687322722812" MODIFIED="2011-01-11 11:43:55 +0000" MODIFIED_BY="[Empty name]" ORDER="584" O_E="0.0" SE="1.248332220738267" STUDY_ID="STD-Staedt-1997" TOTAL_1="11" TOTAL_2="11" VAR="1.5583333333333333" WEIGHT="27.980468833044313"/>
<DICH_DATA CI_END="0.7511775910505197" CI_START="0.31494505253957517" EFFECT_SIZE="0.48639455782312924" ESTIMABLE="YES" EVENTS_1="99" EVENTS_2="126" LOG_CI_END="-0.12425737631737901" LOG_CI_START="-0.5017652095768119" LOG_EFFECT_SIZE="-0.3130112929470955" MODIFIED="2010-03-30 11:47:03 +0100" MODIFIED_BY="[Empty name]" ORDER="585" O_E="0.0" SE="0.22174996995050344" STUDY_ID="STD-Trenkwalder-2007" TOTAL_1="183" TOTAL_2="178" VAR="0.049173049173049176" WEIGHT="51.27978868346198"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2011-01-14 10:08:22 +0000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2010-12-01 09:59:53 +0000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAfMAAADnCAMAAAA94U9AAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAAJAElEQVR42u2daXLjKhSF1SlXsTn+ZatsjqpU3os1MUuANfOddscW
YhJH9wIyx3QdaA3/OkEjtAX9RRs0BziHcwDnAM4BnAM4B3AOrodXE1epIdp69tYG52e4s4t50B98
O/05gHMA5wDOAZyDp3Iugw8r8Q6BjBUopYTbDTiX6qrtqMKqKgXp2/n20YJGS/r7OxqanAKHkNnQ
5oip+O8E0uRsp4xGGo+s0sJYYAHFz+GkGppYDR+V7ViHQDWE9//tiKn48wnV+SllLJKbpXKKGcMV
xG5i5++mlBFXqhZ8bCxcLZxXCwmDUtViURLeN7BzuT5Qk+Gn932i1uMvhCXLlct3KPicc+W0sko0
tPRPj05XZQ2+YmEptyLV0VOE1nx7bziDc5eOncku8hacTsV3WZOJSaFc8yZZdxOoHMP90d6768Fl
myPrrR9ZTc1uIkbj2w5BWhG7dKTpyJTW+bHw7UvYQMdS2rwl8TeiTvP9+c/Ms77wmgmJi76snd8A
rI2y1kbpV1vXCzq+V4NzAOcAzsETgKahuXE7moZW6oOmgf4cwDmAcwDnAM4BnL8xraiRydPy09wX
zqFpOIHzDAHEjt+No2k43bfLQLOQVCJ4woVQ6zBb8HA2jC9ZGLmCI57D+bKFlBKhiwsXnDAjeRg0
D2F8habhHDs3Agjfna+ueY5pJFTqbFJewSLI4+1cVg2/MnLM1EZA+fGcJ/UG1UoEtZAcgs/37ZYA
ImKPsthDyPXkkrvgSmM4S8+wokQIdA1B2JQ8VoA3ZgQJNLLWme/PLU0Dz17x7Q/FL/VpjXM0Ded2
LADOAZwDOAeM4arm5xCNpqE9J4mmgf4cwDmAcwDnAM4BnO8BKacFzeEvgbJPQxHuMz/vfxxaTZ+C
Uy7lrJR5mG+XgdzBCcDCH2PngSW72z44AZj4Mzh3uTRyBxkPwLU/qj/P9AOAuRp4CueJ7Vsw8+f1
53Pf7Soc5gB8exoP1DRE6NZ8f/7z2N9vZ6LWpp1HwNoo9mlg3A7gHMA5gHNwb6BpaG7cjqahFfzS
GPTnAM4BnAM4B3AO7sp59iJhmZNkw9xkUY7s07CCZ87P0TQUcC6HH1ftpr/97zP3YdJ8nKzpHTgs
KLfDxgaX02/qR7Jxkqjl3EyMYeGriZJ4g+p1iBnff6/v4W16zWHf4Wn3k7DDxEo2dpLv1dzswr8j
xXiFfs9XM6P7ah6d1RjeHRDZGsHeEKHYiBb3VYgEL3yKaNVitVLGvYNt+/OscVz2+E6W5DuuZp5/
3Hvy7X6PDjbmPLpFSoX1mzFX8lMi9Th0MG/gw/l5xm4IaZPMNtbYREwm5mjSTR2G2ts4cAuU2nls
uwTrRGe5VGVieVsp9Kei2ThJ+gMniYycstQLrlMP3tA0rKFsrfNdW5KtCbpf9mnAzp8O1kahaWDc
DuAcwDmAc3BvoGlobtyOpqGVq2SfBvpzAOcAzgGcAzgHbXI+7aOwHCcMCo8L19exT0Mptpufry+n
yFxxoT4vGk3Dkb693yZBTnsmSNvsph0U4mcHLyDHf52VjZOp2Y9hPpLs03CWnRsTG63MGNvwSdkH
wdnhpSzrtIzVij/vx2Bn1LFPwyl2PlplVnOr5eBB+BSPrxIZ+WIMXPux/fmijjQUIazIUVdifTR2
gPON6U9bsytCUFneABKvPj9Pm7qMfZTu8dyth6Yu80rmDjnWzj0lmadqSJ2dVNB+RO8o1EnYbhxN
QwbuttZZVj0G0Hx/zj4N2PnjwdooNA2M2wGcAzgHcA7uDTQNzY3b0TS0AvZpoD8HcA7gHMA5gHMA
56soFUCklA7J1ThoGhZw0vx8MwFEPDc0DZf17bkCiFHl4IoZLG9g7cCCgV/Wzo095gggVFTMYGXg
KyUw8QtyLpPbNmQ6cH85daB6wLVfuD8v20hrRQAxr4eF8qv69pjF1o3+pl0dGLzdZH5eb+re3g2W
KgJqr2vnWQIIY7vepg/2vhHjdg749jU0staZx43s04Bvb+Auh+nWOEfTcLlxO4BzAOcAzgGcAzgH
cA7gHM4bgD45/bUywM6xcwDn4Hngt8JaQWu/Ffbpja0/NYwLZIBvpz8HcA4Yw4EnDWhfrVzoMI7T
77+546E5Tf9elNSMm0Rd2WbcJbJrMJwytU4V2gjnerjy/pVN+dRaYjzKT+pMF2rKNsl1l1sD7V1p
slD687X5Xf0sSYvNbtZNS3s1R2UxE7qafu0/GCgvW2TXQGRfcFucC/1+6exx6+Ta/95Lk3Zzysqy
g3yqahBL05idi27u7QpdfEVS8XHZn9Ygnqa5/rykxfSHnvnzbkV8PkII0zCGy+hM6+eHW80zeSZT
Pz8fxsF512zNjkuTBhP82gxESeVj8/NIGs1zuPbcF769PcA5nAM4B3AO4BzcD6/9pv7gWhARzpmp
P3tajm+nPwdwDuAcwDl4xlxtYdZ2lRE9FduNc9/6f69a3Z/LVOyfe/gfvh3AObgF5zrebw2BOqOj
C+JobUL1Wv9YXLMLPEmOVkyHl6wPbrFszkVfXmxosrgYc0ldJdLRxCMe/uulxhKntVi5b9f93Ta9
eeHTjainW1o7UbUdU3s3byrjgiaecohVVR9v+sKrSGCveqyU1sYJ7N9ir4ILEJN4ymjgzJ0bE1Zp
4Z6xj4VJpz0p3yDaqFvKPb+CHDeRj1XejG4L2BXUThsc02JfJXetWPVCb6FM/9+LIJKdQMzX1ZIT
95vivClz3OEK/7OInNqxxV4VHnS6GpF/4SJjlFGccW5/euLYoMpd7d1ir1pjKnCWY9QVpZW2xPUb
kS6cjG+EfVvsq9J+9MKN7d3cOntsq6uMMjKj0DlTzBO9+0rj7Nxir0q/YxzKyHDaw/hR3ZhCzyeH
M7r4xvWKtnMcqyrOJT1oLKum+vgWs7RLOrnT3q9YG5XuMtSNhPrP2y/zHYv/vF3kXtdmrbeW0Xx+
i98QEjuQrp+6Ns9pLL3hbKKgxbb4zYEd+Hnuckyx01UW5BXn/LJbTf5ctWL/3ei2e93KyqjYFuC7
1PYA53AO4BzAOYBzcD/YczXEyM1xjhQZ3w7gHMA5gHMA5wDOAZwDAA7C/yTgN2WcxyJmAAAAAElF
TkSuQmCC
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-12-01 09:59:53 +0000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAATAAAAH4CAIAAABCIiZ9AAAV/UlEQVR42u3dvY4kRbrG8ZJwMMYY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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-05-21 13:23:42 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.1 Change on severity scales.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApEAAACQCAMAAABnNsB1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-05-21 13:23:57 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.2 Periodic limb movements in sleep.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqAAAADACAMAAADsiSGEAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAASm0lEQVR42u1dz671NhH3d3XoIAQSUlVQBYI1Ei/QDeoDeMeeHU/B
o7DjAVj5Idiwgw0rumABtBIUEJ2vQuKeEyf+O/Y4cXKcm5n2u8lJHHtsj2fGzi+ed6CEhMalF2kC
IRFQISERUKG3SDdpgn6klTLzXzKFTWMe6UpphWUR0CfQay9r4zrcCMtleiez+K7q6KFhJl1jVdPU
qbZfte1n7fd+5q/R7un5cE2WxQfdqd/NvdO0MVMP6ukQqKV7kqlrbS9754/0cybzxUuyLALa2RoG
muNuHJfrrflMJ+biLIsPuqPtjExjOWl6Xr54EZZFQHfpZeX5b3zdQ+ktc2GWxcTv1++adPZKScPH
7C+tr8qyCGhvj84snpxxDl3QfSZZxJkvmeC2n4m5KsuyzCQ0NIkGFRIBFRISARUSARUSEgEVEhIB
FToL+W+SFuRfsIJVWtCan6inrNHhuESbXfLeWRvHjInrNZ9pU844eCdDv9quNa2Z2XwwpE1wa+NC
40nY9DXoHYIyQVH4lTSHAG0sTWVZBI3eBkpwrBtTyyi5X6mxRff48InmVnJ4IDMhiHK3NjbnKdi8
5bjWZoam6kWVTBUJkIPzEx6Q1YEHTYQWXK7SKtLoeFD6uMRpjNpEHh5sAy7RlNlIuVczlkKb1UrL
cWiSi0nreBe0r8/3fDs/FpuBD6ptf/pGW2cHzKxUotdiMyZQO40XDiNdH1RH4RJL74rtQ+7xpU56
smGr5NNEHGq/CD3h1nXK5mEWakg2X0J9khZjJSGr+ZInTEk1FW8cjUt0rGtm2xo+N3GD6fAtd7aV
DJH5JBh6Dxk4BZu31Ly3ujG6t705BJe4sG64+W/19ng1cs6MJxyPmas2O+vSIdm85Vhsr1RHwTwM
l5hn3UxqxKJxeo29yXluG/vqYNs+JpsvpFOm64sF3hM6EDFNq0WeqO6OS2TbIa1XKNN5dqnZ6j8u
0E4HXOkmVP1dpOIMbL6EXp91QublLBPZ7wjn5z1hPbTgl/LxgV4CsrkOxCXOrBd9UPd42BArzIaZ
phfRBUVyOM1Fwts62wm9rfxgbPLwoE0laUM9cI7PwNvqVH1MHfLQ5tqNyuaNJZ5tbsme33E/idbV
SeRzOwmiXkhI6I3Qz48v8iYaVIhPx0uLwO2EhiYRUCERUCGh1T6oNIGQUu+nwwdjCyhy3WAEmxyS
w5MpYSZhK7mVZ3y+ihDnDN5FVtnLBVyO8wnkGpRq6OVs6idUl5jf3uI5GgJHCmzC13/h4dnyGTOT
sJXcyjM+X8U0ZwRCPomyvQIgZAGzDUo1tDuzAwWva+LtQLWDNFEE4zYNVBdEgLdqMmushqoCI9v8
XVsKdT33dDddYF+c/zb4ZQYX0EV9QFZFnsGysOxfPRHQDs7Gsn35A37pGDkem8kUfo0noFhRBJC1
9dFhACs/D6gsW+jUo/PxqmIGkwGBh2mlRLBadkWESdFGFbF80Vn87INipnUgduGnvooOT58eRSMp
wxaEHiHFOOR9V8iJCbtsmxAISXMXMZ/PBV/73diOWuLCQ+7wbPcz7nbgPtigonF12bFYI8u6Q6uT
0U4fDCugL6psVFxbqhPY96TrsFwvknHco+zwOgAoaEh/Ucr5oKE1d94X5ZVlbz/Jzj/YgHkZguTa
3cozHl71M5rOgV82xUIi1u7JLC+52lyABA/6PPW+JZV6yrLz8WBqeRd/8ERu0MxONkkS2nMe12nS
dhHTJxpUSARUSEhMvNB6ej+fjLceKhpU6DQalMCD0ssZ4+FCu+FBHSLOpZ6wmN3woH7BCAVevQyU
W40VPChHGtRYuNBueFBbOf/mIhid8KB+3ljiNcSR4TJarrHO9JIVvPurTZyawkrh42j/oWvQwSgL
xYJtizNcAGa97PAaVDLJp+jf6Gh7Ov0x7iQpUIiYDu7xcaHO/q20hDMkBFNfgY8HbUWG1tPPuhn7
Dur368fvoQI640GTV8elce5ZnBHeyUeYzAyuzf2uA13QB+fZ1/BsPCiJ3sS8Wi7yKpOkog9a6EML
V3y2D5rHZBYGSxHIirEdhrCJOHjQ3HzTw4MWCqtMNS8ltcx1UFh573D3s955CAxfsADW5ONBa03l
A+8RODkiVJi7ooBivKY08nhukE8szX7SDyyhQ9lhOn+kYMvXT/2N1AcnEVDvm6TgG5zoV2Iqh8GF
1vGgNkUNDxrWbRc8qOMkKYzK8YokeNCR1HuTRRI8qFD/idygmZ1+kiTUbx7XJZXgQYWERECFhERA
hURAhYQOmCTZPW7WLYcQqNCD10Ia8KAzuBLLEw6MwZ21JUk2LDSDAkVia7DcRqJXxYOunB8SqNCD
10Ja8KCgOFv2YpIzhQetsJDAQjMoUAyKTJkIELh74EHfj/dOidx+0R/2xE6hVpsgqMFeyHOwIlnx
PZ4F5q6g1VutdiZP7+hbMJCApsM+u1MoA7uEQ8O+qY23KxXoJdJJ3tMFoBNC30GU06DDuQ3Ju/gU
YUbpg1hXjPGyGCHy86hdTb1qMJ1uVdsflM3CZonfadwPHkQh3TEsbIjsxc4tv3V6tNTEgSwDLhK8
C/AqMD+XxYO2saBilAjdWvmEcJkN6mkTr7z9WisXS9J4IHCRi8mEpuGDycym4LY0wkLRQfCp1iLg
n1cC+LxUTQiWL5a6O9kC8zi3kuKTuT9oUgHsx0KUt4OFEq3F3kj07WtQ54NmsYwlBGWIXXwWKrRl
f9DIb6nIXB0PWmGBKge5Br+N5TdDggd90jRueyrBgwrtNp8bJpfTTpKE9p7ObU0leFAhIRFQISER
UCERUCGhvSdJNCKhuK0AUjuKJgjRI/x6DFF0KZ6Ouz9oXDs2HpRiob5NKMWQ13SXxoN2w57l9g09
aNaJyxiLzzzp4ewPGu8rxsaDUizUtwmlGYJcy+74Ov79QLCRW04DTJsuekBQX3UsNz1tsKSe3t0h
Vwn315+YlIdE0GZgZOTyg74sKDqWdCEy517oxTjXd+klGEhAM5jPsG2CQe9vH1raN/SQ13Og6sLB
Mo2lbwvKY43DQrv8wK5SAqkGHcZ9uJX59b6FAbT/0duHluLJj7K7EPoxr5uAIAhMPChf8IDl1sdN
d6l38TeW1seySch2cRRP/gDvExq1BbgtaZuUDQ8PWucVGJs1K8jb/F0H+wcnENB4DPsNYr9Zqnko
xwaSB8pta7Vvxcm5YuBBuU4wY11EkDylddDET57sfHQPK1p1rHjyhXk6Uz53m5mQ63YSLz5vn2NX
E2LjreLtQ7NZPBEhmsVQc3Gasd+6rFJW8KAUCxQy1TE0I0Or+4YKHlTo6HGzJpXgQYV2dS6GyOW0
s3ihY6Zz61MJHlRISARUSEgEVEgEVEho70mS2+bC346yhAUdKVI8wWMhXjxr8zDlbycKFTwosuPF
K/ChqhRktoAYbVmMfUuz+BrY0eu3sSLFEzwW9gcNK1GfK9fixScl0huDhvuTkpBZerdTUBvjxb8f
OrpcQUBdw0S7GNURn2db+vAqAUUlHJ310eyZTNNNwgjuWnghOuodeQfGFVCIIsLHhr6G+BzrI4Qq
uBc4bOf2EqcNPLKFJrvVdysaikNAatCTKJNbPDbTDZMR6PpiaNxOEU8y2Ta2wHZgnqvx4vlCkwWE
AB3eGGoZNNJJ7Lvi4EGRNBVRxHUYRwBpmUvhn7xI4/V48czdHCELq4nxH0UdeSn4RGkL8Lk5yD1B
YcgGK8dU38wsGS+esRkq4XMClRCfEiplKHpRsROaQj4pf3tYqKeiN9tsYxYbnmNvhspvRwGIlvCg
3iR3+sZ1QMRnXWq27Q/aEi+eeoRiwXf7I2ToIogRQHTklt6LBA965MJCv1RK8KBCe68fDJTZ+Wbx
QnvN3vqkEjyokJAIqJCQCKiQCKiQkAiokAiokJAIqJCQCKiQCKiQkAiokAiokJAIqJCQCKiQCKiQ
kAiokJAIqFBIH38sAio0Lv3wz//+kQio0Kj045+oz7/8akDGvI/m9OPv8lmU+0BK24uvV/SU4pHU
6Pv5kmy69Zr2CV9W9SU9V9EdvPr5dVZB45np6Cd3z5M3bGN6F8IsYw58RrrRN775+evf7/631jJP
/WjOmOmfL65Rg+l7gqlBH6nDXrW3Mo+eTD5ddVyt5jNDyfTjro6Se62ySFly49GYwYUSB/bQVVS+
+tZdPtU/fj9eb9zyHWS0rzCVipRrqmcfl6Zzo88vn616xIR6tKDdTFZfZ64bIv0eSuzj/73++fAL
9ekffjq+gN4bTGujrSnT2mQ6rmxgzm3kNw0whuVNkujIOzicfv2L+98vlPr8Z+eaJN0llbgzGbR7
s+qTW/RGDUXWedKEnp2+X3i0oMm1XXohuT4r1ySHzgZe/cpNSU42i49bwkqs9VRfXSdtlFFXIrLO
eSnSGbFLx3q59XeXT/W3+xLoh6//PvryDD5oqSXM6adAuzithidFbCPuZ7m/fCr1r+//VX3x6oN+
52QCmpdYrzecs2m0Nns03UALT5SDbRKhua+15ZqilDI4mER/usf2aOSv//PR31990N/88gyzeKMf
4/cuccb3tR7LnpNHZZMEkyf/2hsQU9cKtjq5OidrH36i5EI54zRlvBC6pND9m/jr3336ufreJwN2
RMPudpptn67llnZuPdM5Qyb94J+f/OmzbswdNUlqmd6uSHg5X7WrfPalv3z7j5+N2GqyP6hQwxiT
/UGFhERAhURAhYREQIXePskk6TJUDbpQj8rQIUVr6AfRoEJD0y0R7g0RfuMYgUusOhVdBHJY5WK4
4xKBcEqRjbuI5SjwCLmosd5DqLK5ZoO/B1F3aW5QwbWjxPUW0M2UiSed9g+kEVSSwKAQyyz6UTOh
FAaPjgKPQD8EwRhQadFB7HaI4uvmuSnGlhfaJKBzhLMgTvyiQ8AFlEcbdc39Qi+ufKSI5k5WiRhg
chZpdAhUEpYivGOuOg+GtwgL0M7UCFHIsUsiVAekwLbmvlGO7KQnvDjx7oCebrFXwAkSph0aRp/3
Q9VG4eeBFAo/ynCag5NLIDwPJ+OZh5LRpCphiO550fUJRtwxAsop5pyTpBtPuJNgk3TLQGrXIPOj
GAU7H4wS1uewsAzFkQ2FJEiEyQS6ITrElhcTn7Q1KlaUX2zR241h+7B1coGwIgeEJiUUmgpOxtnY
8kI9fFCod1tL7yI5MYLVIhgZVXao1vpDjZyVMs56xEJdZvGF1aa8g7X8ArrXPTFlCwBQWgsqywVZ
Fc54CFa5Ti3cPIdgc4IeKaCHgMKy8uj5XC5Y+eMscMa8X8tqZeKNhUHoSzIQRk7nh0cncqiUSwyp
MJs0pjtDBmux5Q+e5kO6PJystGSXqaMkqzOoM5HSqledCFtu9yqmYw6tJeHpVuCD1dxSlQrVKt9m
ZtDaeLeVQ/EA+TzS+rXxfL4aItf0rq9aPYNVed9W8tHRy9gxI9inKOhazaNMPPRNuCKDNXnflNAV
iL08tsV5qWWwJm8R0LdOaOELPJ0HHUZCV4soAnoB3bm3+7mnay540KuoUeY8f/NCwSYmUvKWmfJw
i3ldUzW+eowBGPGCoA8eURRC1DM+yfpqG4QzPpxwpajH1AWLa5S1RUqsYRnYS638hr/xXNiNXVl6
I53DYaaozuRNVCOEMzrY5ryOhFYBNsDwCIDjSsAGJpgmHhGXA1rwCM6XcRae6a6K7thnw7xe7/g3
53yRFP/5HVKix2GbGdvXXRLagW75zovA4xE0NLKQKWg0ygsC1Ojjfx9Rmdp6qI49hAbrQ49lEdQT
CmhFp4cv2SH4GIMrJFDWl1xV595qiaBdSUCtKuMrJaTtLNaN8Oa3a23MCp1eQKE+aaIEJUF+AtvJ
zk7n2cIr30/acEvs5Kb9zsqiyvlWiru1T7tVaONjScKihow/bfZxpBuV69U1qHmTRb3khA4fazjT
YRG4+Xf6yzsHRMjkFWcMbjngPsOPp/5O1pe1gpRJcsjg/NFpUI+oVm93Mv8IQaInPTeFI5l/uCtk
0jmsy/zgfFFvKUq7YDFBKXoprFDILaOEIP0B8c0gEQSn4E+XwJ8+Rc+UQEGQLyP50pNSpJA8EmXw
VvXtI7aVSc+nn8GVTFIbvG2+Y6+YvCFmF6Xn6JFBnrxCTvuqs8fXPm9LgU4qaIn2p5mx6+Kk6bnZ
WpRJ8zZcf+G8YBEYIovxfNDi3uAmiNTA3UZcby8qlxOreEEzvUUTX5RibRrnOlSWLUXlnmAVL2im
t7ngFAVF15TS0mTS4FxvKiqTpXfQokEvtdikXTRca2W9S4Hd9X+ESec7RkfPrytqCWvmsjeZQrIq
VTawFSra9mdnIyZeaGgSDSo0NIkGFRIBFRISARUSARUSEgEVEhIBFRIBFRISARV66/R/Sb5+ZfiY
YCwAAAAASUVORK5CYII=
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-05-21 13:24:48 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.5 CGI-Improvement.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApEAAACQCAMAAABnNsB1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-05-21 13:25:05 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.06" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.6 Change in self rated quality of sleep.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAArUAAACQCAMAAAAhgGPfAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2011-01-13 10:04:52 +0000" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.07" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.7 Change in quality of life.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAApEAAACQCAMAAABnNsB1AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-05-21 13:25:35 +0100" MODIFIED_BY="[Empty name]" NO="8" REF_ID="CMP-001.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Levodopa versus placebo, outcome: 1.8 Number of patients experiencing adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAr8AAADACAMAAAA6LPvhAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-12-01 15:14:07 +0000" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-002.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Levodopa versus other dopamine agonists, outcome: 2.1 Change on IRLS.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAvYAAACQCAMAAABUDd98AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2011-01-14 10:08:22 +0000" MODIFIED_BY="[Empty name]" NO="10" REF_ID="CMP-002.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Levodopa versus other dopamine agonists, outcome: 2.4 Number of dropouts due to adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuEAAACwCAMAAACW00DbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2011-01-11 11:43:56 +0000" MODIFIED_BY="[Empty name]" NO="11" REF_ID="CMP-002.08" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Levodopa versus other dopamine agonists, outcome: 2.8 Number of patients experiencing adverse events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAuEAAACwCAMAAACW00DbAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2010-11-30 15:47:57 +0000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-11-30 15:47:30 +0000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2010-11-30 15:47:30 +0000" MODIFIED_BY="[Empty name]">MEDLINE (OVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-06-02 13:29:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>randomized controlled trial.pt.</LI>
<LI>controlled clinical trial.pt.</LI>
<LI>randomized.ab.</LI>
<LI>placebo.ab.</LI>
<LI>drug therapy.fs.</LI>
<LI>randomly.ab.</LI>
<LI>trial.ab.</LI>
<LI>groups.ab.</LI>
<LI>or/ 1-8</LI>
<LI>humans.sh.</LI>
<LI>9 and 10</LI>
<LI>AF L-dopa</LI>
<LI>AF "L dopa"</LI>
<LI>AF Ldopa</LI>
<LI>AF levodopa</LI>
<LI>or/ 12-15</LI>
<LI>AF "rls"</LI>
<LI>AF "restless leg*"</LI>
<LI>17 or 18</LI>
<LI>11 and 16 and 19</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-11-30 15:47:38 +0000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2010-11-30 15:47:38 +0000" MODIFIED_BY="[Empty name]">CENTRAL (ODVID) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 09:22:44 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>AF L-dopa</LI>
<LI>AF &#8221;L dopa&#8221;</LI>
<LI>AF &#8221;Ldopa&#8221;</LI>
<LI>AF levodopa</LI>
<LI>or/1-4</LI>
<LI>AF &#8220;rls&#8221;</LI>
<LI>AF &#8220;restless leg*&#8220;</LI>
<LI>6 or 7</LI>
<LI>5 and 8</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-11-30 15:47:46 +0000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-11-30 15:47:46 +0000" MODIFIED_BY="[Empty name]">PsycINFO (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 09:23:12 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>TX L-dopa</LI>
<LI>TX Ldopa</LI>
<LI>TX &#8220;L dopa&#8221;</LI>
<LI>TX levodopa</LI>
<LI>or/ 1-4</LI>
<LI>TX &#8220;rls&#8221;</LI>
<LI>TX &#8220;restless leg*&#8220;</LI>
<LI>6 or 7</LI>
<LI>5 and 8</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2010-11-30 15:47:57 +0000" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2010-11-30 15:47:57 +0000" MODIFIED_BY="[Empty name]">CINAHL (EBSCO) search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-13 09:23:53 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>TX L-dopa</LI>
<LI>TX &#8220;L dopa&#8221;</LI>
<LI>TX Ldopa</LI>
<LI>TX levodopa</LI>
<LI>or/1-4</LI>
<LI>TX &#8220;rls&#8221;</LI>
<LI>TX &#8220;restless leg*&#8221;</LI>
<LI>6 or 7</LI>
<LI>5 and 8</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-04-24 13:18:09 +0100" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2009-02-13 09:24:16 +0000" MODIFIED_BY="[Empty name]">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-02-18 15:08:19 +0000" MODIFIED_BY="[Empty name]">
<OL>
<LI>(random* or factorial* or crossover* or "cross over*" or placebo* or (doubl* adj blind*) or (singl* adj blind*) or assign* or allocat* or volunteer*).mp </LI>
<LI>Randomized Controlled Trial/ </LI>
<LI>(l-dopa or levodopa* or ldopa or "l dopa").mp </LI>
<LI>Levodopa/ </LI>
<LI>(rls or "restless leg*").mp </LI>
<LI>Restless Legs Syndrome/ </LI>
<LI>(1 or 2) and (3 or 4) and (5 or 6)</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>